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1. Introduction 
 
1.1. In January 2020 the Home Secretary commissioned the Advisory Council on the 
Misuse of Drugs (ACMD) to review the evidence for the classification of gamma-
hydroxybutyric acid (GHB), gamma-butyrolactone (GBL) and related compounds 
under the Misuse of Drugs Act 1971 (MDA), and the scheduling of these 
compounds under the Misuse of Drugs Regulations 2001 (MDR).  
 
1.2. In February 2020 the ACMD notified the Home Secretary that it would expect to 
provide initial advice by autumn 2020 and would also provide advice on other 
approaches that the available evidence suggests would be of value in reducing the 
availability, demand, and harms of GHB, GBL and closely related compounds. 
 
1.3. The Home Secretary’s commission had been prompted by the suspected usage of 
GHB or a closely related compound in the criminal cases of Reynard Sinaga, and 
(separately) Stephen Port and Gerald Matovu.  
 
1.4. This report reviews the evidence of harms of GHB and related compounds that have 
emerged since the ACMD’s last significant assessment of the risks of GHB and its 
prodrugs, GBL and 1,4-butanediol (1,4-BD) in [ACMD, 2008a]. The aim is to enable 
the ACMD to assess the level of harms associated with these compounds and to 
make recommendations to mitigate these harms – including (but not limited to) 
recommendations on the most appropriate classification and scheduling of these 
compounds under the MDA and MDR respectively. 
 
1.5. For the purposes of this report, the closely related compounds to be considered in 
addition to GHB by the ACMD in response to the Home Secretary’s commission are:   
• GBL;  
• 1,4-BD;  
• gamma-hydroxyvaleric acid (GHV); and 
• gamma-valerolactone (GVL). 
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2. Previous ACMD advice and legal status of GHBRS- UK 
 
2.1. In the UK, drugs deemed suitable for control under the Misuse of Drugs Act 1971 
(MDA) are designated as either Class A, B or C substances and typically placed in 
any of Schedules 1 to 5 of the Misuse of Drugs Regulations 2001 (MDR) to enable 
their legitimate use. The current legal status in the UK of the compounds being 
considered by the Advisory Council on the Misuse of Drugs (ACMD) in this report 
(gamma-hydroxybutyric acid [GHB], gamma-butyrolactone [GBL], 1,4-butanediol 
[1,4-BD], gamma-hydroxyvaleric acid [GHV] and gamma-valerolactone [GVL]) is 
given in Table 1. The chemical structures of the compounds being considered in this 
report are given in Annex A. 
 
Table 1: The current legal status of the compounds being considered in this 
report 
 
2.2. Since 2003 GHB has been controlled as a Class C drug under the MDA. At this time 
GHB was also placed in Schedule 4, Part 1 of the MDR since a GHB-based 
medicine (Xyrem®) is used in the treatment of narcolepsy and prescribed at low 
levels in the UK. GBL and 1,4-BD remained uncontrolled until an ACMD report was 
initiated in 2008 by concerns that users of GHB may have switched to using GBL 
and 1,4-BD (since they rapidly convert in the body to the intoxicant GHB) [Wood et 
al., 2008; US Department of Justice 2002], with further evidence of switching 
reported subsequently [Anderson et al., 2011; Corkery et al., 2015; van Amsterdam 
et al., 2015; Busardò et al., 2018].  
 
2.3. The report [ACMD, 2008a] provisionally recommended that GBL and 1,4-BD should 
be controlled under Class C of the MDA and Schedule 1 of the MDR (having no 
recognised medical use), with licensing arrangements to allow their legitimate 
industrial use (they are used in large quantities in the chemical industry) [ACMD, 
Compound 
name 
Classification 
under the MDA 
Schedule under the MDR 
GHB C 2 
 
GBL C Unscheduled (regulation 4B of the MDR makes it lawful to 
import, export, produce, supply, offer to supply or possess 
these substances except where a person does so knowingly 
or believing that they will be used for the purpose of human 
ingestion) 
 
1,4-BD C Unscheduled (regulation 4B of the MDR makes it lawful to 
import, export, produce, supply, offer to supply or possess 
these substances except where a person does so knowingly 
or believing that they will be used for the purpose of human 
ingestion) 
 
GHV Unclassified Unscheduled 
 
GVL Unclassified Unscheduled  
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2008a]. However, the report also recommended a government consultation 
specifically on the impact of control on the legitimate use of GBL and 1,4-BD in the 
chemical industry. Responding after the consultation, the ACMD advised that it 
would be disproportionate to recommend control of GBL and 1,4-BD with no 
concession to the legitimate uses of the substances [ACMD 2008b]. The ACMD 
recommended prohibiting the possession, supply, production and 
importation/exportation for GBL and 1,4-BD, with the inclusion of a licensing 
regimen for industrial use. However, the approach taken by the Government was to 
regulate and limit the offences to where these substances are possessed or 
supplied for human consumption. In December 2009 GBL and 1,4-BD were 
classified as Class C drugs under the MDA [Home Office, 2009]. Although they were 
not placed into a Schedule of the MDR, Regulation 4B of the MDR makes it lawful to 
import, export, produce, supply, offer to supply or possess these substances except 
where a person does so knowingly or believing that they will be used for the 
purpose of human consumption. This aimed to allow the legitimate use by the 
chemical industry, whilst regulating use for human consumption.  
 
2.4. In 2013 the Home Office requested updated advice from the ACMD regarding the 
scheduling of GHB following the World Health Organisation (WHO) rescheduling 
GHB from Schedule IV (drugs presenting a risk of abuse, posing a minor threat to 
public health, with a high therapeutic value) to Schedule II (drugs presenting a risk 
of abuse, posing a serious threat to public health, with a low or moderate 
therapeutic value) of the Convention on Psychotropic Substances of 1971. GHB 
was, at the time, in Schedule 4, Part 1 of the MDR.  
 
2.5. In the light of the WHO decision, the ACMD reviewed the evidence and agreed that 
the abuse liability of GHB is substantial whereas the therapeutic use is little to 
moderate in the UK [ACMD, 2013]. The ACMD therefore recommended that GHB 
should be rescheduled under the MDR to Schedule 2, which was brought into law in 
2014.  
 
2.6. Given that GBL and 1,4-BD are converted in the body to GHB upon ingestion, GHB, 
GBL and 1,4-BD all display very similar psychoactive effects – and are also 
considered synonymous by users. Therefore, for the majority of this report, evidence 
of GHB harm can be assumed to be equivalent to GBL and 1,4-BD harm unless 
otherwise stated. When referring to GHB, GBL and 1,4-BD in this report, the 
abbreviation for GHB and related substances (GHBRS) will be used. 
 
2.7. GHB can be easily manufactured from GBL and 1,4-BD. Therefore, some countries 
(Italy, Latvia, Sweden) have chosen to control one or both precursors under drug 
control or equivalent legislation [EMCDDA, 2008].  
 
2.8. Unlike GBL and 1,4-BD, GVL is not metabolised to GHB in the body but is instead 
metabolised to GHV. Because of its activation of the gamma-aminobutyric acid 
system, GHV reveals similar effects to GHB, but it is less potent – therefore, for the 
purposes of this report, evidence of GHB harms are not considered to be equivalent 
to that of GHV or GVL harms. 
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3. Chemistry and pharmacology  
 
3.1. Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are structurally related to 
gamma-hydroxybutyric acid (GHB) and both are converted within the body to GHB 
[Roth and Giarman, 1966; Busardò et al., 2018]. Therefore, all three substances 
have similar psychoactive effects [Wong et al., 2004; Fjeld et al., 2012; Castro et al., 
2014; Busardò and Jones, 2015]. All three substances are considered to have the 
same withdrawal syndrome [Lingford-Hughes et al., 2016; Floyd et al., 2018] and 
withdrawal has been observed in individuals with dependence for GHB, GHB/GBL 
co-ingestion, GBL, and 1,4-BD [Catalano et al., 2001; Wojtowicz et al., 2008; 
Zvosec et al., 2011; Evans and Sayal, 2012; Corkery et al., 2015].  
 
3.2. The National Drug Intelligence Centre (NDIC) in the USA considers GHB analogues 
to be GBL, 1,4-BD, gamma-hydroxyvaleric acid (GHV) and gamma-valerolactone 
(GVL) [US Department of Justice, 2002], as they produce similar effects to GHB. 
GVL is a substance that metabolises into GHV, which has similar effects to GHB 
[Bourguignon et al., 1988; Carter et al., 2005].  
 
GHB  
3.3. GHB occurs naturally in the brain [Bessman and Fishbein, 1963; Snead and Morley, 
1981] and is both a precursor for and a breakdown product of the inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA) [Vayer et al., 1985; Busardò 
and Jones, 2015]. GHB acts as a neuromodulator in the brain promoting relaxation 
and sleep. The effects of GHB are similar to alcohol in that they can both cause 
euphoric effects in small doses and sedative effects in larger doses [Miotto, 2001; 
Zvosec and Smith, 2005; Oliveto et al. 2010; Bay et al., 2014; Neptune, 2015]. 
However, one of the major differences between GHB and other drugs, including 
alcohol, is that it has a very steep dose-response curve [Gable, 2004; van 
Amsterdam et al., 2012; Korf et al., 2014]. This means there is a narrow margin 
between a dose that results in desired effects, and a dose that results in adverse 
effects. For GHB this margin can be in the magnitude of a few grams, discussed 
more in chapter 6.  
 
3.4. The mechanism(s) of action of GHB are still a matter of debate. There is literature 
suggesting that there is a high affinity binding site for GHB in the brain, sometimes 
referred to as the ‘GHB receptor’ [Laborit, 1964], but the existence of a specific 
receptor is still not generally accepted. It has been proposed that GHB may activate 
subtypes of the GABA-A receptors and be a partial agonist at GABA-B receptors 
[Szabadi, 2015; Venzi et al., 2015; Ritter et al., 2020]. The interaction with GABA-A 
receptors may result in euphoria, increased libido and sociability whereas interaction 
with inhibitory GABA-B receptors may result in sedation, respiratory depression and 
hypotension [Bay et al., 2014]. 
 
3.5. Several early studies researching the pharmacokinetics of GHB in healthy 
volunteers [Palatini et al., 1993; Borgen et al., 2003; Brenneisen et al., 2004; 
Abanades et al., 2006; Helrich et al., 2008] showed that GHB is rapidly absorbed, 
metabolised to carbon dioxide, and rapidly eliminated [Brailsford et al., 2012]. There 
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are numerous routes of administration (see chapter 5), but when GHB is ingested 
the effects usually occur 15 to 20 minutes after ingestion and can last for up to 3 or 
4 hours [Gonzalez and Nutt, 2005], with peak effects 30 to 60 minutes after 
ingestion [Schep et al., 2012]. GHB is rapidly eliminated, demonstrated by a half-life 
of 20 to 30 minutes [ibid.]. Elimination is mainly through the lungs, with less than 5% 
of GHB excreted in urine [Neptune, 2015]. GHB is undetectable in urine after 
approximately 12 hours [EMCDDA, 2002].  
 
GBL 
3.6. GBL is a precursor of GHB and is non-enzymatically converted in the body into 
GHB. On ingestion GBL is converted to GHB with faster acting but identical 
psychoactive effects [Wood et al., 2008; Busardò and Jones 2015; Veerman et al., 
2019]. 
 
3.7. GBL is more potent than GHB because of higher lipid solubility, which facilitates 
rapid passage across the blood-brain barrier to achieve high concentrations at its 
site of action in the brain [Palatini et al., 1993; Brunt et al., 2014]. It also has longer 
duration of action [EMCDDA, 2002].  
 
3.8. GBL is a colourless, odourless liquid and is approved for use in the chemical 
industry (see chapter 4). It is also available as a common solvent for several 
products, including nail polish remover and cleaning products. It can be relatively 
easily bought over the internet [Veerman et al., 2019] for either legitimate or illicit 
use. GBL can be used as a precursor to GHB, and GHB synthesised illicitly is most 
commonly produced using GBL as a starting reagent [EMCDDA, 2008; Giorgetti et 
al., 2017; Veerman et al., 2019].  
 
3.9. GHB synthesised illicitly could contain cutting agents that could also be harmful, or 
cause a harmful drug interaction; however evidence of this is limited. One study 
reports sildenafil (Viagra) as an adulterant systematically added to GHB, which 
caused additional harm to the user (see chapter 7) [Pichini et al., 2016].  
 
1,4-BD  
3.10. 1,4-BD is a precursor to GHB and converts into GHB in a two-stage conversion in 
the liver through enzymatic biotransformation [Corkery et al., 2015; Castro et al., 
2019]. The distribution and rate of conversion of 1,4-BD to GHB influence the 
desired/undesired pharmacological actions [Bosch and Seifritz, 2016]. 1,4-BD has a 
similarly steep dose-response curve to GHB, with a narrow safety window [Stefani 
and Roberts, 2020]. There is evidence of inter-individual variability of 1,4-BD 
pharmacokinetics, so there is variation in an individual’s susceptibility to overdose 
due to different absorption and conversion rates [Thai et al., 2007].  
 
3.11. Recent literature has shown that 1,4-BD intoxication causes coma and recovery 
symptoms similar to those seen with GHB [Nunez et al., 2018]. However, more 
recent literature has revealed that a 1,4-BD-induced coma can last longer than 
those associated with GHB, with patients recovering more slowly due to more 
prolonged central nervous system (CNS) depression [Stefani and Roberts, 2020]. 
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The first case report of a confirmed 1,4-BD intoxication in Portugal provides 
additional evidence that 1,4-BD induces a profound coma and can be abused in 
place of GHB [Castro et al., 2019].  
 
3.12. The major difference between GHB and 1,4-BD is the rate of elimination in the body, 
with 1,4-BD elimination/metabolism being slower than that of GHB, meaning its 
effects last longer [Corkery et al., 2015; Stefani and Roberts, 2020].  
 
GHV/GVL 
3.13. GVL is a drug that can be ingested and is metabolised into GHV. GHV has similar 
psychoactive effects as GHB, as it has an affinity for the same receptors as GHB 
[Bourguignon et al., 1988]. However, this affinity is approximately half that of GHB, 
as determined by rat brain preparations [Carter et al., 2005]. Therefore, it would be 
expected that GHV/GVL would have similar effects on behaviour as GHB but be 
less pronounced (at the same dose).  
 
3.14. In an early animal study, the administration of GVL produced muscular weakness, 
mild anaesthesia and an increase in respiration rate. These signs were followed by 
dyspnoea, mild asphyxia convulsions and death at higher doses [Deichmann et al., 
1945]. More recently, GHV has been shown to have similar effects as GHB in rat 
brains, causing sedation, catalepsy and ataxia, although larger doses of GHV were 
required to produce these effects [Carter et al., 2005].  
 
3.15. GHV exists as a mono-sodium crystalline salt but is often mixed in a liquid where it 
is colourless and cannot be identified [US Department of Justice, 2002]. GVL exists 
as a colourless liquid at room temperature.  
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4. Therapeutic and other legitimate uses of GHBRS 
4.1. The Advisory Council on the Misuse of Drugs (ACMD) has consulted with the 
Medicines and Healthcare products Regulatory Agency (MHRA) in establishing 
whether there are any withdrawn, current or pending licences for any products 
containing the compounds being investigated in this report to identify therapeutic 
uses. The ACMD has also consulted with the Department for Business, Energy and 
Industrial Strategy (BEIS) and stakeholders within the chemical industry to establish 
the extent of the legitimate industrial uses of the compounds being investigated in 
this report. 
 
Therapeutic uses 
4.2. A gamma-hydroxybutyric acid- (GHB)-based medicine (Xyrem) is used in the 
treatment of narcolepsy and is effective in improving narcolepsy-cataplexy related 
symptoms [Xu, 2019]; it is prescribed at low levels in the UK. Figures for England 
from the NHS Business Service Authority (NHSBSA) show 1,711 items of sodium 
oxybate (Xyrem or GHB) 500mg/ml oral solution were dispensed in primary care in 
2019 [NHSBSA, 2020]. These figures are only from primary care settings, so do not 
reflect prescribing in other settings for example, hospitals, and are therefore likely to 
be an underestimate of the total prescribing level in the UK.  
 
4.3. Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are prodrugs for GHB, but 
the MHRA has confirmed they are not themselves found in any medicinal products 
with withdrawn, current or pending licences. The MHRA has also confirmed that 
there are no withdrawn, current or pending licences for any products containing 
gamma-hydroxyvaleric acid (GHV) or gamma-valerolactone (GVL) so consider there 
to be no legitimate medicinal uses of these compounds that it is aware of. 
 
Industrial/commercial uses 
4.4. In its 2008 report on GBL and 1,4-BD, the ACMD reported extensively on the 
legitimate industrial uses of those two compounds [ACMD, 2008a]. GBL and 1,4-BD 
were then, and still are, widely used in UK industry. Both chemicals are imported 
and utilised in significant volumes in a wide variety of processes by the chemical 
industry and are distributed by chemical distribution companies. There is no 
authorised UK manufacture of GBL or 1,4-BD, as such these compounds are 
imported in large volumes to the UK for industrial use. GBL and 1,4-BD imports are 
typically from non-EU countries.  
 
4.5. Many of the companies that handle GBL and 1,4-BD in the UK are members of the 
Chemical Business Association (CBA), which represents members’ interests in the 
UK and Europe and promotes industry standards. The CBA reported that these 
compounds are primarily imported and/or sold for industrial applications – with a 
small volume going into consumer market materials. In 2019 the volume of GBL and 
1,4-BD sold by CBA members was in excess of 300,000kg and 500,000kg 
respectively.  
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4.6. The main use of GBL is as an intermediate in the synthesis of n-methyl-pyrrolidone 
(NMP), pyrrolidone, herbicides (for example, MCPB = γ-2-methyl-4-
chlorophenoxybutyric acid), growth regulators (for example, α-(4-
methylbenzylidene)-γ-butyrolactone [5418-24-6]), α-acetobutyrolactone (a vitamin B 
intermediate), and the rubber additive thiodibutyric acid. GBL is used as a solvent 
for polymers and as a polymerization catalyst; in hair‐wave compositions and sun 
lotions; and in pharmaceuticals. It is also used in printing inks, for example, for ink-
jet printing; as an extractant in the petroleum industry; as a stabilizer for 
chlorohydrocarbons and phosphorus-based pesticides; and as a nematicide. More 
recent applications are in the electronics field as a cosolvent for capacitor 
electrolytes and as a cosolvent for photoresists. 
 
4.7. 1,4-BD is a versatile intermediate for the chemical industry and an intermediate for 
GBL and tetrahydrofuran. The most important application is the production of 
polyurethanes and polyesters, for example, poly (butylene terephthalate). Among 
the polyurethanes produced from 1,4‐BD, cellular and compact elastomers are of 
prime importance. Polybutylene terephthalate is processed particularly to plastic 
materials and hot‐melt adhesives but is used also for the production of plastic films 
and fibres. 
 
4.8. After consultation with stakeholders from the chemical industry and BEIS, the 
ACMD has not identified any significant industrial uses of GHB, GHV or GVL in the 
UK. 
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5. Recreational use 
 
5.1. Gamma-hydroxybutyric acid (GHB) acts mainly as a central nervous system 
depressant, however different doses can give varying effects. At low doses GHB 
can give euphoric and stimulant-like effects, but at higher doses it can be sedative. 
GHB/gamma-butyrolactone (GBL) also affects people in different ways, and a 
euphoric dose for one person may be a sedative dose for another [Kam and Yoong, 
1998]. Therefore, recreational users of GHB should not assume that a dosage that 
gives them a desired effect would be the same for another individual.  
 
5.2. The desirable effects of GHB include relaxation, euphoria, confidence boosting, 
disinhibition, increased sociability, social and sexual disinhibition, enhanced libido, 
increased sexual arousal and enhancement of sexual encounters, with effects being 
dose-dependent [Luby et al., 1992; Henderson and Ginsberg, 2008; Galicia et al., 
2011; Schep et al., 2012]. 
 
5.3. GHB is used recreationally as a club drug, as the desirable effects tend to be 
produced without hangover [Palatini et al., 1993; Abanades et al., 2007]. Some 
people also use GHB after using other drugs, such as stimulants, to enhance or 
modify their effect [Miotto et al., 2001], or to help their ‘come down’ [Degenhardt et 
al., 2002] after the initial high.  
 
5.4. GHB and related substances (GHBRS) are also used to self-medicate for anxiety 
and/or sleep problems. It is also used in the hope that it will reduce the effects of 
ageing, improve cognitive ability, reduce depression, and boost energy levels [Stein 
et al., 2011]. Previously GHB was also used in bodybuilding; however, its anabolic 
affects are unproven [Nicholson and Balster, 2001], and recent literature does not 
appear to support use in this context.  
 
Routes of administration of GHB and related compounds  
 
5.5. GHB is a solid white compound that has a high solubility in aqueous solvents where 
it is colourless and odourless. It has a slight salty-bitter taste but is often difficult to 
detect in flavoured beverages [Veerman et al, 2019]. For recreational purposes 
GHB is most commonly sold as a colourless liquid in the UK, usually in bottles or 
vials. It can also be sold as powder, usually GHB sodium salt (capsules or loose) or 
a waxy substance/paste to which water can be added [EMCDDA, 2008].  
 
5.6. GBL and 1,4-butanediol (1,4-BD) exist as colourless liquids, so are sold for 
recreational purposes as such, usually in bottles or vials.  
 
5.7. There are a number of different administration routes for GHBRS, however oral 
ingestion is by far the most common. Outside oral ingestion there is a lack of 
evidence on the mode of administration.  
 
o Oral ingestion usually involves dilution of GHB, GBL or 1,4-BD in a beverage for 
drinking. The beverage masks their unpleasant salty taste. Although uncommon, 
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swallowing GHB capsules has also been reported [Evans and Sayal, 2012]. GHB 
has irritant properties, so it is thought capsules may be easier to ingest. 
 
o Insufflation (snorting) is uncommon for GHB and not possible for GBL or 1,4-BD 
due to their liquid state.  
 
o Mucosal is, again, relatively uncommon, but possible for GHB, GBL and 1,4-BD.  
i. Rectal insertion of these drugs has been reported by mixing or dissolving 
the drug in a small amount of water and inserting into the anal passage 
using a wide-bore oral syringe. The drugs pass through rectal membranes 
and are absorbed. This technique is sometimes referred to as ‘plugging’ and 
was a route of administration used by Stephen Port on a number of his 
victims under the pretext of administering lube [Pettigrew, 2019]. It is 
thought this was done to see if this method would result in faster onset of 
action.  
 
ii. Another example of mucosal administration is absorption of GBL contained 
in nail polish remover pads when held against the gum.  
 
5.8. Injection of liquid GHB, GBL or 1,4-BD is very uncommon.  
 
5.9. The GHB/GBL dose is often measured by users in imprecise ‘capfuls’, teaspoons, 
eye droppers, vials, or the sushi fish shaped plastic containers. This imprecise dose 
measurement is considered to be one of the main reasons for acute GHB/GBL-
related harms, as users risk overdose because of its steep dose-response curve 
[Neptune, 2015].  
 
5.10. Although purity and concentration of GHB and GBL vary, typically 1mL of liquid 
contains 1g of GHB [Miotto et al., 2001; EMCDDA, 2008; de Jong et al., 2012]. The 
size of a single GHB dose also varies depending on the individual and can range 
from 0.5g to 5g (0.5ml to 5ml for a typical concentration). The typical size of a single 
GBL dose varies between 0.5ml and 1.5ml, but individual responses vary. Even a 
very small dose, below 1ml, could lead to overdose without warning [NHS, 2020].  
 
5.11. Recreational users typically take small doses frequently in the context of binges, or 
sometimes at night to help them sleep [Neptune, 2015]. Dependent users ingest 
GHB/GBL more frequently, at regular intervals, and over prolonged periods, 
including throughout the night [Miotto et al., 2001]. Anecdotal evidence was reported 
from a GHB-dependent user who took 2ml doses every hour during the day and 3ml 
every 2 hours at night. A wide range of dosing intervals have been reported [Sivilotti 
et al., 2001; Chew and Fernando, 2004; de Jong et al., 2012], with an average of 
4.4 hours between doses for dependent users [McDonough et al., 2004]. People 
who have developed dependence report using more than 25g of GHB in a single 
day [Miotto et al., 2001].  
 
5.12. As GBL is more lipophilic, and therefore more potent than GHB, the doses are 
smaller and 1.5g is typically considered a single dose [Couper and Marinetti, 2002].  
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Availability of GHB and related compounds 
 
5.13. GHB retailers are easy to find on the internet, as are instructions for making GHB 
[Sanguineti et al., 1997; EMCDDA, 2002; 2008]. Individuals can use these recipes 
to manufacture GHB themselves after easily obtaining precursors such as GBL 
[Brunt, et al., 2014].  
 
5.14. GBL for recreational use in the UK is usually bought from street dealers or via the 
internet in amounts ranging from 125mL to 10L [Neptune, 2015]. According to 
anecdotal reports from a GHB user who underwent detoxification two months prior 
to commenting, GHB/GBL dealers typically buy the substances online and users 
purchase them face to face. The same GHB user reported in June 2020 that the 
approximate street value for GHB/GBL is £50 per 100ml (in Manchester). Assuming 
a recreational dose of 2ml (although this varies) this equates to GHB/GBL costing 
£1 per recreational dose. A news report from Manchester also reported the cost of 
GHB/GBL to be £1 per recreational dose [Manchester Evening News, 2020]. It 
should be noted that it has previously been reported that the price of GHB differs 
depending on locality [ACMD, 2008a]. However, the Bristol Drugs Project reported 
that 1ml of GHB or GBL costs £1 in Bristol too, regardless of the volume bought. 
Online searches indicate that this is generally the case across the UK, with the 
drugs costing under £1 per 1ml (so under £2 per average recreational dose) even 
when buying at the lowest volume.    
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6. Prevalence and patterns of GHBRS use 
 
6.1. General population use of gamma-hydroxybutyric acid and related substances 
(GHBRS) in the UK has typically been low. The use of GHB appears to be 
concentrated among certain groups, such as men who have sex with men (MSM), 
or in in specific contexts such as nightclubs [Neptune, 2015]. There was a steep 
increase in GHBRS use in the UK, specifically in England, from 2005 to 2015. Since 
then the evidence suggests a plateauing in use, but a small and steady pattern of 
use and harm. It is suspected that general population prevalence is still relatively 
low, but this is difficult to determine due to lack of systematic data collection [Brunt 
et al., 2014; van Mechelen et al., 2019].   
 
6.2. In the absence of general population data in the UK, sources of evidence outlined in 
this chapter include:  
• National Drug Treatment Monitoring System (NDTMS) data;  
• presentations with acute GHBRS toxicity to emergency departments (EDs);  
• addiction service access data;  
• National Poisons Information Service (NPIS) data;  
• Independent Drug Monitoring Unit; and  
• drug seizures data.  
 
6.3. These sources of evidence are not all available across the UK and additional 
evidence specific to devolved administrations are also included.  
 
England, Wales, Scotland and Northern Ireland 
 
England 
6.4. The NDTMS collects data from statutory drug treatment services in England. Its 
annual reports reveal an increase of new presentations to treatment services with 
GHB/gamma-butyrolactone (GBL) related problems, as shown in Figure 1. Whilst 
there is a general increase in the number of new treatment presentations citing 
GHBRS as a problem drug, the peak appears to be in 2015/16, and after that a 
plateau to approximately 2014/15 levels. 
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Figure 1: The number of new treatment presentations citing GHBRS as a 
problem drug each year from 2005–06 to 2018–19  
 
Source: Public Health England 2019 data tables [PHE, 2019, Table 11.5]. 
 
6.5. When data from Figure 1 are considered as a proportion of new presentations 
involving ‘club drugs’ for that year, there is an increase from 1% in 2005–06; 6% in 
2013–14; to GHB/GBL related problems representing 8% of new club drug 
treatment presentations in 2018–19. 
 
6.6. The PHE-NDTMS data also present a breakdown of all clients in treatment and their 
associated problem drugs. In 2016 there were 553 people in treatment services 
citing GHBRS as a problem drug, equivalent to 0.2% of people in drug treatment 
services in England [PHE, 2016]. In 2018–19, this number decreased to 454; 
however, this still represented 0.2% of the treatment population [PHE, 2019]. 
Therefore, for those in treatment services, the proportion of GHBRS related 
addiction has remained fairly constant in recent years. In comparison to other drugs 
the number of GHB presentations to treatment is low. 
 
6.7. Presentations with acute GHB/GBL toxicity to the ED and clinical toxicology service 
at London Guy’s and St Thomas’s Hospital increased from 158 in 2006, to 270 in 
2010 [Wood et al., 2013].The European Drug Emergencies Network (Euro-DEN) 
reported equally high number of ED presentations at the same hospital in 
[EMCDDA, 2015], evidencing 293 GHB/GBL-related presentations over the course 
of 2013–14, accounting for 31% of all drug-related ED presentations, beating 
cocaine (n=171), mephedrone (n=126) and heroin (n=111). The same study 
revealed, however, that two other UK EDs did not report the same high proportions 
of GHB/GBL-related presentations (as shown in Table 2).  
 
6.8. The high rate of GHB/GBL representation is only seen in the London hospitals in the 
EuroDEN data, with York reporting zero presentations. Localised prevalence can be 
linked to Guy’s and St Thomas’s Hospital proximity to Vauxhall, a well-established 
and popular night time economy for the LGBT community. York hospital may be 
more representative of the picture nationally, but this is difficult to determine without 
data from other UK hospitals being included in the EuroDEN data collection.   
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Table 2: UK data extracted from the 2015 Euro-DEN data set, data collected for a 
12-month period, October 2013 to September 2014 
 
Number of 
drug-related 
presentations  GHB/GBL Cocaine Heroin Cannabis Mephedrone 
London Guy’s 
and St 
Thomas’s 
Hospital 956 293 171 111 96 126 
London King’s 
College 
Hospital 422 87 90 72 77 27 
York Hospital  202 0 16 91 27 23 
Total 1,580 380 277 274 200 176 
Source: [EMCDDA, 2015] 
 
6.9. The numbers of individuals seeking help from services such as Antidote (substance 
misuse service provided for the lesbian, gay, bisexual and trans-gender [LGBT] 
community by the non-governmental organisation London Friend) and the Club 
Drug Clinic, Central North West London NHS Foundation Trust (CNWL) for GHB-
related problems has increased.  
 
6.10. Antidotes report an increase in the proportion of individuals presenting with GHB-
related problems from 1.7% (n=3) of total referrals in 2005, to 57% (n=317) in 2010; 
this subsequently fell to 44% (n=334) in 2013–14 [Lingford-Hughes et al.,2016]. 
 
6.11. It is possible that the steep increase in GHBRS-related hospital presentations and 
service access from 2005 to 2015 may be due to an increase in problematic use 
amongst those who already use GHB, or an increase in the strength of available 
GHBRS. However, from the literature reviewed, it is thought that this is marginally 
more likely to be due to an increase in prevalence of GHBRS use. Therefore, it can 
be inferred from the data that GHB use increased in the UK population until 2015. 
Since then, the evidence suggests a plateauing in use, but a small and steady 
pattern of use and harm.  
 
Wales 
6.12. The Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) 
project received 18 samples submitted as, or found to contain, GHB between May 
2014 and August 2020. Of the 18 samples submitted, only 7 met the project’s 
acceptability criteria and were analysed (five from Wales, one from England and one 
from Scotland). One contained GHB, five GBL, one 1,4-BD and one was found to 
have no active compounds present. This is evidence that all three compounds are 
used in Wales, with an initial indication that GBL is the most prevalent [WEDINOS, 
2020, data request].  
 
6.13. The Welsh National Database for Substance Misuse (WNDSM), collected by NHS 
Wales, collects treatment reports across primary, secondary and tertiary care 
settings. These data report low prevalence with between 4 and 12 individuals in 
treatment per annum from 2014 to 2020 [Welsh Government, 2019]  
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6.14. Over the last five years in Wales there have been three deaths where GHB was 
mentioned on the death certification. One in each of 2015, 2017 and 2018. This 
again indicates low prevalence of GHBRS use in Wales.  
 
Scotland 
6.15. There appears to be limited evidence of use of GHB or GBL in Scotland. The 
Scottish Drug Misuse Database (SDMD) assessed the number of individuals at 
specialist drug treatment services in Scotland who had reported use of GHB in the 
previous 30 days. In every year between the financial years 2006/07 to 2018/19, 
under seven cases were reported per year as using GHB as their main drug. In the 
same period, under 10 cases were reported per year as using GHB at all within the 
last 30 days [Public Health Scotland, 2019].  
 
6.16. Summary reports prepared by consultant Dr Richard Kennedy (Sandyford Sexual 
Health Services, NHS Greater Glasgow and Clyde) and the ‘Social Media, Men Who 
Have Sex With men, Sexual and Holistic Health Study (SMMASH)’ which is 
undertaken by Glasgow Caledonian University (and covers Scotland, Wales, 
Northern Ireland and the Republic of Ireland), both indicate a low incidence of 
disclosed GHB within sexual health settings in Scotland, with those disclosures 
recorded primarily being experienced by gay, bisexual, and MSM (GBMSM) within 
the context of chemsex [Strongylou and Frankis, 2020]. However, the true levels of 
GHBRS use within these settings may be higher. 
 
6.17. Between the years 2000 and 2018, GHB was ‘implicated in, or potentially 
contributed to, the cause of death’ in 26 cases. GBH was ‘present in the body but 
not considered to have had any direct contribution to the death’ in a further 13 
cases. No deaths involving GBL, 1-4 BD, gamma-hydroxyvaleric acid (GHV) or 
gamma-valerolactone (GVL) were reported between the years 2000 and 2018. Data 
have not yet been published for the year 2019 [National Records of Scotland, 2018]. 
The information suggests that GHB is a relatively minor problem when it comes to 
drug deaths in Scotland – pathologists report that it is involved in only a few deaths 
per year, and that it is usually jointly implicated as the cause of death with other 
substances. 
 
6.18. Statistics on drug seizures made by Police Scotland show there have only been two 
confirmed seizures of GHB between the years 2014 and 2018, both of which were in 
2015 and 2016 [Police Scotland, 2018]. This represented 0.5% of Class C drug 
seizures in 2015–16. GHB and GBL are not frequently recovered by the police in 
Scotland (four cases of GBL in 2019). Scotland has confirmed that there is an 
increasing awareness of GHB and GBL use within the police force. It is suspected 
that there are many more people consuming GBL than the data indicate, but it is 
difficult to identify as its status as a wheel cleaning product means that those in 
possession of GBL are less likely to come to the attention of the police.  
 
 
Northern Ireland 
6.19. There is an absence of data on prevalence and harms from GHBRS in Northern 
Ireland and GHBRS are not routinely appearing in surveys, seizures, treatment or 
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other datasets. It is unclear to what extent this reflects prevalence or data reporting 
systems. 
 
UK 
 
6.20. Overall reported population prevalence was low in England and Wales in 
2011/2012; 0.13% in the Crime Survey for England and Wales (CSEW) [Home 
Office, 2012], an increase from 0.04% the previous year. Unfortunately, data on 
GHB/GBL use were not collected in later CSEW surveys, so more recent general 
prevalence data are not available.  
 
6.21. The NPIS reports data on access activity on its online poisons information database 
TOXBASE® and details of telephone enquiries by health professionals. These data 
reflect (but do not measure directly) the frequency of contacts from health 
professionals and patients following suspected exposure.  
 
6.22. TOXBASE® is an online portal for clinicians holding information on diagnosis, 
treatment and management of acute poisoning from many substances, including 
GHBRS. Data pooled from four service units (Birmingham, Cardiff, Edinburgh and 
Newcastle) over the last 5 years, show that GHB, GBL, 1,4-BD and GHV account 
for 4.3% of all TOXBASE® accesses relating to drugs of misuse (see Table 3). 
Since 2016/17 there has been a small overall reduction in TOXBASE® accesses 
relating to these four compounds, with a slight uptake reported in 2019/20. In 
2018/19 GHB was the tenth most common substance of misuse involved in online 
TOXBASE® accesses. There has also been an increase in TOXBASE® access to 
information on GHV since 2017/18. 
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Table 3: Data showing the TOXBASE® accesses and telephone call data relating 
to GHBRS from 2015/16 to 2019/20 
 2015/16 2016/17 2017/18 2018/19 2019/20 5-year 
totals 
TOXBASE® accesses for 
GHB, GBL, 1,4-BD and GHV 
3,322 3,529 2,692 2,137 2,418 14,098 
% relating to GHB, GBL, 1,4-
BD and GHV 
4.9% 5.5% 4.2% 3.2% 3.5% 4.3% 
All drugs of misuse 
TOXBASE® accesses 
67,228 64,015 63,373 66,227 68,195 329,038 
Telephone calls GHB and 
GBL 
24 18 24 28 31 125 
% of calls relating to GHB 
and GBL 
1.5% 1.5% 1.9% 2.3% 2.3% 2.0% 
All drugs of misuse 
telephone calls 
1,613 1,210 1,245 1,220 1,112 6,400 
Source: NPIS, 2020. The TOXBASE® data include GHB, GBL, 1,4-BD, and GHV. The 
telephone call data include GHB and GBL. The 2019/20 data have been shared ahead 
of publication 
  
6.23. The NPIS provides a national telephone service to advise clinicians in cases of 
acute poisoning, including toxicity relating to drug misuse. Over the last 5 years 
GHB and GBL have accounted for 2.0% of telephone enquiries that relate to 
substances of misuse with no material increase during this time (evident from Table 
3). Neither GHB nor GBL featured in the top ten drug misuse telephone enquiries in 
2018/19 [NPIS, 2019].  
 
6.24. In 2016 less than 3% of festival goers reported ever using GHB [Independent Drug 
Monitoring Unit, 2016] In 2018/19 there were 68 seizures of GHB by police forces in 
England and Wales, weighing a total of 0.72 kg (CSEW presentation to ACMD, PHE 
Drugs and Alcohol Unit).  
 
Globally 
6.25. A comprehensive overview of the prevalence of GHB/GBL usage globally is 
hindered because there are no comparable systematic data collections at an 
international level, along with many countries having different user populations and 
patterns of use [van Mechelen et al., 2019]. This has been known for a number of 
years, with previous studies concluding that overall prevalence cannot be 
determined due to lack of systematic surveillance [Brunt, et al., 2014]. Whilst 
population-level analysis is missing, there are other pieces of evidence indicating 
increased use in a number of countries.  
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6.26. In the 2014 Global Drug Survey GHB/GBL did not appear in the top 20 drugs ranked 
by last year’s proportional prevalence use for any of the countries taking part (of 
which there were 18: Australia, Belgium, Brazil, Denmark, France, Germany, 
Hungary, Mexico, New Zealand, Portugal, Republic of Ireland, Scotland, Spain, 
Slovenia, Switzerland, The Netherlands, UK and USA), with the exception of The 
Netherlands where it ranked 15th at 7.2% [Winstock, 2014].  
 
6.27. According to previous European drug reports, the prevalence of non-medical use of 
GHB is low in the general population [EMCDDA, 2008; 2015; 2017a], but is higher in 
LGBT and MSM [Miró et al., 2017]. According to the EMCDDA’s most recent 2019 
report, whilst there has been reported use of GHB and its prodrug GBL among 
some drug users in Europe for the last two decades, where national estimates exist, 
current prevalence still appears to be low. For example, in its 2017 survey the last 
year prevalence among adults in Norway (aged 16 to 64 years) was 0.1% 
[EMCDDA, 2019].  
 
6.28. In 2015 and 2017 seizures of GHB or GBL were reported by 16 European countries 
[EMCDDA, 2017a; 2019]. There was an estimated total of 1,300 seizures (of GHB 
or GBL) across these countries in 2015 and 1,600 seizures in 2017. These seizures 
amounted to 320kg and over 1,500 litres in 2015, compared with 127kg and 1,300 
litres in 2017 [ibid.]. For the 2017 data, Belgium seized almost half of the total 
quantity, mainly as GBL [EMCDDA, 2019].  
 
6.29. GHB was reported as the fourth most common recreational drug implicated in 
intoxication presentations in EDs in Europe in 2015 and in 2019, after heroin, 
cocaine and cannabis [EMCDDA, 2015; 2019; Dines et al., 2015]. This is strong 
evidence of GHBRS use, and harm, across Europe. However, 85% of presentations 
associated with GHB/GBL were from London (UK), Oslo (Norway) and Barcelona 
(Spain), demonstrating that GHBRS use is particularly localised and that these cities 
have a high prevalence [EMCDDA, 2015].   
 
6.30. There is particular evidence of GHBRS use in The Netherlands. As discussed above 
it was the only country in the 2014 Global Drug Survey where GHB/GBL featured on 
its top 20 drug ranking by prevalence. In addition, a web survey in 2013 showed that 
21.8% of regular nightlife participants aged 15 to 35 years had ever used GHB and 
5.1% did so in the last year [Goossens et al., 2014]. GHB accounted for the largest 
proportion of non-fatal overdoses reported by Dutch emergency services in 2013 
[Vogels et al., 2013], and in 2017 almost a third of drug-related ambulance call outs 
in The Netherlands were linked to GHB use [EMCDDA, 2019]. 
 
6.31. In Asia prevalence is thought to be low, but there are indications that GHB usage 
has increased, particularly among MSM [Wei et al., 2012]. 
 
6.32. It should be noted that most literature does not differentiate between GHB, GBL and 
1,4-BD in terms of prevalence of use. For the most part literature rarely includes 
GHV/GVL as part of this group of drugs; this may be because evidence of use is 
new and limited, or because their use is low.  
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6.33. GHV/GVL was detected in humans for the first time in 2013 in three individuals 
through toxicology analysis [Andresen-Streichert et al., 2013]. One of the individuals 
was suspected to be the victim of a drug-facilitated sexual assault (DFSA) and the 
other two individuals were suspected to be regular GHV/GVL users. The reason for 
the low number of GHV/GVL identifications in literature may be due to low levels of 
use, but the case report authors comment that it is more likely because toxicology 
laboratories do not routinely test for GHV or GVL [ibid.]. Prior to this case, authors 
have reported anecdotal evidence that GVL is used as a legal alternative to 
GHB/GBL [US Department of Justice, 2002; Palmer, 2004; Carter et al., 2005], 
however this is the first case report confirming presence by toxicology.  
 
Pharmacosex and chemsex  
 
Pharmacosex  
6.34. ‘Pharmacosex’ is a phrase coined for a broad discourse on the creative ways that 
wider populations (than the typically considered LGBT and MSM populations) 
experiment with a range of different drugs that modify and enhance their sex lives 
[Moyle et al., pre-publication]. Pharmacosex considered the duality of sex and 
drugs, where sometimes sex is used to enhance, disinhibit or mitigate drug 
experiences, just as drugs are used to enhance and disinhibit sexual experiences 
[ibid.]. The authors drew on qualitative data from two separate studies conducted 
between 2018 and 2019. Participants of both studies identified across a range of 
sexual orientations. GHB/GBL was used in combination with sex in 27% of the total 
number of interview participants, showing that people with a wide range of sexual 
orientations combine GHBRS and sex.  
 
6.35. ‘Chemsex’ (see below) is considered a specific form of ‘pharmacosex’.  
 
Chemsex 
6.36. Within UK and global prevalence trends, there is evidence to suggest that certain 
population sub-groups use the drug more than others. This is particularly true for 
MSM in the context of chemsex.  
 
6.37. ‘Chemsex’ is a colloquial term used to describe sex between MSM that occurs 
under the influence of drugs, which are taken immediately preceding and/or during 
the sexual session for the purpose of enhancing the sexual experience. Chemsex is 
often higher risk, with more partners, not using barrier protection such as condoms 
and of longer duration than other sex [Bourne, 2015a]; group sex is common. 
GHBRS is one of a number of drugs used in chemsex (either in combination or 
alone), as it has been found to enhance sexual experience, prolong the length of 
intercourse and make people more attracted to their partner [Kapitány-Fövény et al., 
2015; Hibbert et al., 2019].  
 
6.38. When considering GHB-specific chemsex, again prevalence is hard to determine. 
Data from 1,472 attendees at two London sexual health clinics reported lifetime 
prevalence of use of GHB at 19% and GBL at 13% [Thurtle et al., 2015].  
 
6.39. There is evidence in the UK that engaging in GHB-related chemsex is more 
prevalent amongst LGBT and MSM sub-groups compared with heterosexual 
chemsex [Bourne et al., 2014; Mohammed et al., 2016; PHE, 2020b].  
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6.40. PHE-NDTMS data hold information on both GHB prevalence in new treatment 
presentations, and on the sexual orientation of those receiving treatment, but these 
two pieces of data are not presented together in PHE-NDTMS tables – i.e. the 
relative proportions of different sexual orientations within the cohort who cite GHB 
as a problem drug in the treatment data set. However, PHE-NDTMS data provided 
information to the ACMD that 12% of all gay/bisexual clients presenting to treatment 
services in 2019 had cited GHB use, compared to less than 0.1% for heterosexual 
men [PHE, 2020b]. Of all 502 clients presenting to treatment in 2019 citing GHB, the 
vast majority (75%) were gay/bisexual men (16% were heterosexual men, 7% were 
heterosexual women and 2% gay/bisexual women) [ibid.]. It is important to note that 
whilst the prevalence of GHB chemsex use is higher amongst MSM compared to 
other groups, a minority of MSM engage in the practice; with only a proportion of 
these reporting associated harms [Hibbert et al., 2019].   
 
6.41. There is also research showing that men who are living with HIV more commonly 
use chemsex drugs than those who are HIV negative or of unknown status [EMIS, 
2013; Kirby and Thornber-Dunwell, 2013; Hunter et al., 2014;  Theodore et al., 
2014; Bourne, 2018; Frankis et al., 2018; Hammoud et al., 2018; O’Reilly, 2018; 
PHE, 2020a].  
 
 
In conclusion, whilst exact prevalence data are unknown, it is predicted that 
overall use in the UK and in each devolved administration is low, with more 
evidence of use in England than in other devolved nations. There is also 
consensus across literature that: 
• there was a steep increase in GHBRS use in the UK, specifically in England, 
from 2005 to 2015;  
• since 2015 the evidence suggests a plateauing in use, but a small and 
steady pattern of use and harm;  
• use is higher amongst LGBT groups, particularly gay and bisexual men; 
and  
• in the UK there is higher use within specific contexts, for example, 
chemsex. 
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7. Physical health harms 
 
7.1. Gamma-hydroxybutyric acid (GHB) has a steep dose-response curve, meaning 
there is a narrow dose margin between the desired and adverse effects [Gable, 
2004; van Amsterdam et al., 2012; Korf et al., 2014]. Even a small increase in dose 
can cause serious toxic effects such as impaired consciousness, coma, and death. 
GHB use frequently causes comas lasting between one and four hours, which often 
score the most critical classification on the Glasgow coma scale (GCS) [Abanades 
et al., 2006; Schep et al., 2012; van Amsterdam et al., 2012; Korf et al., 2014; 
Busardò and Jones, 2015; Miró et al., 2017]. The steep dose-response curve of 
GHB differentiates it from other drugs, and significantly increases risk of harm 
[Neptune, 2015].  
 
7.2. In addition, the narrow safe dose range for GHB varies between individuals, and 
adverse effects occur at a variety of doses [Chin et al., 1998; Kam and Yoong, 
1998]. Imprecise dosing of illicit GHBRS as described in chapter 5 further increases 
the risk of harm. Therefore, alongside the intrinsic toxicity of the substance, the 
hazard profile of GHB is considered more harmful than many other psychoactive 
substances. The severity of adverse effects is influenced by:  
• the dose ingested (which is difficult to measure); 
• individual variation in response; and  
• whether other substances have been co-ingested [Neptune, 2015].  
 
7.3. This chapter outlines the physical harms from GHB and related substances 
(GHBRS) use including: 
• mortality; neurological;  
• cardiovascular;  
• respiratory;  
• gastroenterological;  
• physiological and psychological dependence;  
• physical harms from polydrug use with GHBRS; and  
• physical harms from GHBRS use in chemsex.  
 
Mortality 
 
7.4. Due to the GHBRS steep dose-response curve, there is a narrow dose margin 
between the desired  and adverse effects. Therefore, overdose is a significant risk, 
which can result in death.  
 
7.5. Literature reports increasing number of deaths attributed to GHB since the 1990s in 
Australasia, the UK, the USA, western Europe, and other developed countries 
[Caldicott et al., 2004; EMCDDA, 2008; Zvosec et al., 2011; Corkery et al., 2015]. 
More recent studies show that this trend is continuing; furthermore these numbers 
are likely to be an underestimate because GHB and analogues are not routinely 
included in toxicology post-mortem investigations and can be difficult to detect.  
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UK  
7.6. The Office for National Statistics (ONS) collects data on drug poisoning and deaths. 
The figure below shows the number of drug-related poisonings where GHB was 
mentioned on the death certificate [ONS, 2019]. These data relate specifically to 
‘GHB’ being mentioned on the death certificate and does not capture GBL, 1,4-BD 
or other related drugs. The data are for England and Wales combined and include 
GHB used in isolation, GHB taken with alcohol, and GHB taken with other drugs.  
 
Figure 2: Data on deaths where GHB is mentioned on the death certificate 
  
[Source: ONS, 2019]  
 
 
7.7. The ONS data show an increasing trend for GHB deaths in England and Wales over 
the last 18 years. However, overall, they still represent a small proportion of all drug-
related deaths with the 27 deaths recorded in 2018 representing only 0.6% of all 
reported drug-related deaths (4,393). This is supported by analysis of data from the 
UK’s National Programme of Substance Abuse Deaths (NPSAD) database, which 
showed that there were 159 GHB-related deaths in the UK in the 17 years between 
1995 and 2012 [Corkery et al., 2015], corresponding to approximately 0.5% of drug-
related deaths (≈ 32,000). Both the ONS data and NPSAD data are likely to be 
underestimates due to challenges in post-mortem toxicology and the voluntary 
nature of coroners contributing to the NPSAD.  
 
7.8. Of the 159 deaths reported in NPSAD, 21 were lesbian, gay, bisexual and trans-
gender (LGBT) individuals. These 21 deaths were analysed in more detail, revealing 
GHB was implicated in 11 and the remaining 10 cases involved gamma-
butyrolactone (GBL); none were attributed to 1,4-butanediol (1,4-BD) [Corkery et al., 
2018].  
 
London  
7.9. A more recent study concluded that the number of deaths associated with GHB 
have increased in London in recent years, with an 119% increase in GHB-
associated deaths in 2015 compared with 2014 [Hockenhull et al., 2017]. Between 
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2011 and 2015 the study reported there were 61 deaths associated with GHB 
(0.92%) out of the 6,633 deaths referred to a coroner that underwent toxicology 
analysis [ibid.]. It is important to note that the Hockenhull study reports GHB 
associated deaths, meaning that GHB was present in some form; however the 
Corkery studies report GHB-related deaths, meaning the GHB was considered to 
contribute to the death. 
 
Globally 
7.10. Global mortality trends are difficult to determine due to lack of comparable data. 
However, there is evidence of GHB-associated deaths in Australia, Canada, and 
USA. [Zvosec et al., 2011; Darke et al., 2020].  
 
Post-mortem GHB analysis 
7.11. Interpretation of post-mortem GHB toxicology results (where available) can be 
challenging as GHB is an endogenous substance and can be naturally present as a 
metabolite. Additionally, levels increase post-mortem even during sample storage, 
for both blood and urine samples [Busardò et al., 2014].  
 
7.12. Different studies use different definitions and methodologies for identifying a GHB-
related fatality, making cross study comparisons difficult. There is a lack of 
consensus on the fatal GHB concentration [Hockenhull et al., 2017]. The majority of 
papers use post-mortem blood levels of 50mg/L as the minimum threshold to 
indicate GHB/GBL ingestion rather than endogenous production [Kugelberg et al., 
2010; Zvosec et al., 2011; Corkery et al., 2015], and hence cause of death; other 
authors use a cut-off of 30mg/L. However, some research reports GHB blood 
concentrations in excess of 50mg/L, and up to 193mg/L, for deaths unrelated to 
GHB use [Korb and Cooper, 2014].  
 
7.13. In addition, the short half-life of GHB means the peak concentration may be missed 
on post-mortem measurement, which presents further difficulty in identifying the 
cause of death. In a recent study, 12 cases had GHB concentrations below 50mg/L, 
the generally accepted threshold, and 4 had no detectable blood GHB, but all were 
confirmed as death due to GHB from detection of GHB in ingested substances 
[Darke et al., 2020]. A large range of GHB concentrations are observed in post-
mortem blood samples for GHB-associated deaths: 0 – 6,500mg/L [Corkery et al., 
2015], 108–2,444mg/L [Hockenhull et al., 2017], 13–1,350mg/L [Darke et al., 2020].  
 
7.14. Due to the challenges in interpreting GHB concentration post-mortem, some 
researchers cite the need for evidence of proximity of consumption, for example, 
detection in a drink rather than using a threshold concentration [Kintz et al., 2004; 
Busardò and Pichini, 2017; Darke et al., 2020]. In some toxicology laboratories GHB 
would need to be confirmed in more than one sample type, for example, in post-
mortem blood and urine before a GHB-related death is considered. This is not 
always possible because of limited sample volumes and the availability of 
specimens at autopsy. Another problem in identifying deaths caused by GHB is 
polydrug use, as it may be difficult to describe a death as purely GHB-related if 
other drugs are also detected or reported.  
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Demographics and cause of deaths 
7.15. The manner of death reported in the literature is mainly accidental drug toxicity 
[Caldicott et al., 2004; Knudsen et al., 2010; Kugelberg et al., 2010; Corkery et al., 
2015; Hockenhull et al., 2017], with a notable minority due to trauma or suicide 
[Hockenhull et al., 2017; Corkery et al., 2015; Zvosec et al., 2011].  
 
7.16. Deaths from GHB and related substances (GHBRS) have occurred mostly in men, 
accounting for 70% to 98% of deaths in recent studies [Hockenhull et al., 2017; 
Darke et al., 2020]. Most deaths are reported in young people, typically those in 
their 30s [Caldicott et al., 2004; Zvosec et al., 2011; Corkery et al., 2015; Hockenhull 
et al., 2017; Darke et al., 2020]. A history of drug use is also common, with 
prevalence ranging from 57% to 81% [Hockenhull et al., 2017; Corkery et al., 2018]. 
In addition, GHB was taken in combination with other drugs in 92% of deaths [Darke 
et al., 2020], highlighting the dangers of polydrug use for GHB. Alcohol was found to 
be a fairly common co-ingestant and was present in 20% to 25% of deaths, but the 
most common co-usage was stimulants, for example, cocaine or methamphetamine, 
which were present in 64% to 72% of deaths [Hockenhull et al., 2017; Darke et al., 
2020]. This is additional evidence, alongside that in this chapter relating to overdose 
and drug co-ingestion, demonstrating that the presence of alcohol or other 
substances increases the risk of harm from GHB [Gonzalez and Nutt, 2005; Liechti 
et al., 2006; Galicia et al., 2011; Department of Health, 2011; Miró et al., 2017].  
 
7.17. Deaths occurred mainly in the home of the deceased or their friends and was more 
likely to occur at the weekend [Corkery et al., 2015; Hockenhull et al., 2017; Darke 
et al., 2020].  
 
7.18. In [Corkery et al., 2015] 21 out of 159 GHB-related deaths (13%) were LGBT 
individuals. As discussed in chapter 6, there is evidence that prevalence of GHBRS 
use is significantly higher amongst LGBT individuals than in the general population. 
Therefore, it is striking that 87% of deaths are not LGBT. This could be because use 
is higher amongst other groups in the population than has been identified in the 
literature thus far, or it could be that in the mortality data sexuality is not always 
captured or reported. Three London boroughs accounted for 62% of the GHB-
related deaths in LGBT individuals; considered to reflect the concentration of 
resident and visiting gay individuals [Corkery et al., 2018]. In addition, of the 
individuals who died from GHB (n=61) in [Hockenhull et al., 2017], 33% (n=21) had 
been living with HIV, significantly higher than observed in other drug-related deaths 
(8% for ecstasy-related deaths and 3% cocaine).  
 
Deaths involving GBL and the GHB/GBL equilibrium  
7.19. The literature relating specifically to GBL related deaths, where GHB is not also 
present, is sparse, with only five reports globally between 2001 and 2019 [Duer et 
al., 2001; Lenz et al., 2008; Dargan et al., 2009; Küting et al., 2019]. However, there 
is evidence of GHB-related deaths involving GBL in addition to GHB, with 55 
(34.6%) of the 159 GHB-related deaths in the UK between 1995 and 2012 involving 
GBL as well as GHB [Corkery et al., 2015].  
 
7.20. GHB and GBL have previously been found to be in equilibrium with one another in 
aqueous solutions [Ciolino et al., 2001; Dahlén et al., 2011]. In a case report of a 
man who died after ingesting GHB, the concentration of GHB in the beverage he 
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ingested increased significantly over a 16-month period [Küting et al., 2019]. This 
demonstrated that GBL was present and had established an equilibrium with GHB. 
The GHB/GBL equilibrium means that identifying the presence of GBL is difficult in 
toxicology analysis [ibid.]. In addition, some laboratory methods require the 
conversion of any GHB in the sample to GBL before it can be analysed [Ingels et al., 
2014], adding additional challenge. Therefore, the prevalence of GBL-related deaths 
within the GHB reported deaths is unknown. 
 
Relative harm 
7.21. A publication in 2018 calculated the fatal toxicity index for new psychoactive 
substances (NPS) including GHB/GBL [King and Corkery, 2018]. The toxicity index 
was developed based on data from death certificates by calculating the ratio of 
deaths to prevalence and seizures. The research also showed that calculating the 
number of deaths from sole use of a particular drug, divided by the number of 
deaths where that drug was listed alongside others on the death certificate, is also a 
measure for the fatal toxicity potential of a substance. A significant finding was that 
GHB (alongside other drugs such as methyltryptamine, synthetic cannabinoid 
receptor agonists and benzofurans) had a higher fatal toxicity than other NPS, whilst 
benzodiazepines analogues had a particularly low fatal toxicity index [ibid.].  
 
In conclusion, there is evidence of increasing deaths associated with GHBRS 
since the Advisory Council on the Misuse of Drugs last considered the harms of 
GHB in 2003, and GBL and 1,4-BD in 2008. Although overall mortality numbers are 
low, there has been a marked increase in deaths between 2008 and 2018. Mortality 
figures are likely to be an underestimate due to the challenges in testing for and 
identifying GHBRS post-mortem. When GHBRS mortality is compared with other 
NPS drugs, there is evidence that they have a higher risk of fatality.  
 
Emergency department presentations and hospital admissions 
 
7.22. GHB was reported as the 4th most common recreational drug implicated in 
intoxication presentations in emergency departments (EDs) in Europe in 2015 after 
heroin, cocaine and cannabis, with 711 reports of GHB across Europe in 12 months, 
out of a total of 5,529 presentations involving 8,709 drugs in drug-related hospital 
presentations [Dines et al., 2015; EMCDDA, 2015]. This was supported by the 2019 
report with GHB being the 4th most common again, representing over 10% of 
intoxication presentations across Europe [EMCDDA, 2019]. This provides evidence 
that despite low levels of use (see chapter 6), there appears to be high levels of 
morbidity associated with GHBRS use.  
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Figure 3: The top 25 drugs recorded in emergency presentations in sentinel 
hospitals, 2017: Results of 7,267 presentations in 26 Euro-DEN plus (sentinel) 
hospitals in 18 European countries. 
 
Source: European Drug Emergencies Network (Euro-DEN) Report, [EMCDDA, 
2019].  
 
7.23. GHB accounts for the largest proportion of non-fatal overdoses reported by Dutch 
emergency services [Vogels et al., 2013], and in 2017 almost a third of drug-related 
ambulance call outs in The Netherlands were linked to GHB use [EMCDDA, 2019]. 
A review of ambulance records on pre-hospital treatment of overdoses in Norway 
between 2009 and 2015 showed 1,112 cases of GHB and GBL poisoning, with GHB 
suspected for 89% of patients [Madah-Amiri et al., 2017]. This again demonstrated 
that despite the low prevalence of use, morbidity associated with GHBRS use is 
high.  
 
7.24. To view England and UK ED presentation data, please see EuroDEN statistics 
presented in chapter 6.  
 
7.25. In 2019, 133 Freedom of Information requests were submitted by Buzzfeed News 
and Channel 4 Dispatches to NHS trusts across England and Wales. They found 
that most hospitals do not test specifically for GHB/GBL in overdose patients. Some 
hospitals do record the number of admissions related to GHB/GBL and in the year 
to November 2018, four hospitals (Blackpool, Portsmouth, and London – King’s 
College Hospital and Guy’s and St. Thomas’) reported that they had 700 
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presentations where GHB/GBL had been used. Unfortunately there is no more 
granularity presented in these data.  
 
7.26. The evidence given here demonstrates that GHBRS toxicity is significantly 
represented in hospitals and clinical care settings in Europe [Vogels et al., 2013; 
Dines et al., 2015; Madah-Amiri et al., 2017; EMCDDA, 2015; 2019].  
 
Neurological, cardiovascular and respiratory harms  
 
7.27. Symptoms of GHBRS toxicity span neurological, cardiovascular and respiratory 
harms.  
 
Symptoms of acute toxicity 
7.28. Mild/moderate symptoms: Shortly after ingestion of GHB or its analogues, 
individuals may experience drowsiness, dizziness, shallow breathing, slow heart 
rate, low blood pressure, nausea or vomiting, muscle spasms and seizures 
(myoclonus), and hypersalivation [Chin et al., 1992; Li et al., 1998; Thai et al., 2006; 
Schep et al., 2012; Korf et al., 2014; Neptune, 2015]. 
 
7.29. More severe symptoms: the hallmark of GHB intoxication is a rapid and profound 
coma that is usually associated with slow heart rate (bradycardia), slow breathing 
(hypoventilation), and respiratory depression, followed by a full recovery within four 
to eight hours, often requiring supportive care for survival. The coma is 
accompanied by loss of bowel/bladder control, headaches, amnesia and 
convulsions, respiratory arrest, and in some cases cardiac arrest. More recent 
literature supports this evidence with coma leading to the characterisation of 
intoxication as severe and an intensive care setting advised [Chin et al., 1992; Miró 
et al., 2002; Couper et al., 2004; Snead and Gibson, 2005; Liechti et al., 2006; Thai 
et al., 2006; Knudsen et al., 2008; Munir et al., 2008; Wood et al., 2008; Galicia et 
al., 2011; Schep et al., 2012; Dietze et al., 2014; Dines et al., 2015; Neptune, 2015;  
Madah-Amiri et al., 2017].  
 
Single dose and chronic use toxicity  
7.30. There are harms associated with any use of GHB, whether this is one-off, binge or 
dependent use. All users risk acute toxicity and overdose, and tolerance for GHB 
does not protect a user from harm.  
 
7.31. In terms of single-dose toxicity, GHBRS appear to be the most toxic club drug 
[Neptune, 2015]. Overdoses typically occur as a result of taking large doses in a 
short period of time, or when taken in combination with other central nervous system 
(CNS) depressants, such as alcohol or benzodiazepines [Gonzalez and Nutt, 2005]. 
One study in mice suggests that whilst tolerance is reported for GHB sedative 
effects, this is not the case for respiratory depression [Morse et al., 2017]. 
Therefore, taking a single dose of GHB has same risk of respiratory arrest in GHB 
overdose for chronic users as for binge or one-off users. 
 
7.32. For chronic or dependent users, non-lethal overdose causing coma or blackout has 
been recognised as a common occurrence for some time [Chin et al., 1992; Duff 
2005; Degenhardt and Dunn, 2008]. Recent literature further supports this finding. 
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7.33. In The Netherlands a recent survey of 146 GHB users found more than 9 in 10 
respondents had ever slipped into a light sleep, referred to as ‘G-napping’, often 
more than once. Over two thirds (69%) reported having been in a drug-related coma 
at least once; 14% experiencing a coma in the last month. About 10% had 
experienced coma extremely often (more than 100 times), including 9 respondents 
who reported over 250 comas, with a maximum of 1,800 comas reported for one 
individual [Grund et al., 2018]. The average number of comas experienced was 81, 
with a median of 6 [ibid.].  
 
7.34. In Switzerland it was found that 64% of GHB-related ED presentations were 
comatose [Liakoni et al., 2016]. 
 
7.35. In Australia, 14.7% of GHB users had experienced coma at least once [Hammoud et 
al.,  2018]. 
 
7.36. In a case series of GHBRS presentations to a London ED in 2006, there were 158 
GHBRS presentations in total. Of these 158, 24 (around 16%) had a Glasgow Coma 
Scale (GCS) score of 3, meaning severe coma on presentation and 72 (around 
48%) had a GCS score of less than or equal to 8, which is the usual cut-off for 
intubation [Wood et al., 2008]. 
 
7.37. A higher lifetime use of GHB consumption increases the likelihood of coma, as does 
‘stacking’, which is the cumulative number of GHB doses taken in an episode of 
drug taking, with more stacking increasing the likelihood of coma [Grund et al., 
2018].  
 
7.38. The circumstances of the overdose are typically accidental overdoses in night clubs 
[EMCDDA, 2002]. ED admissions for GHB use were mostly young males [Madah-
Amiri et al., 2017; Miró et al., 2017], consistent with the prevalence of use data.  
 
7.39. Recent literature has shown that 1,4-butanediol (1,4-BD) intoxication has coma and 
recovery symptoms similar to that seen with GHB [Nunez et al., 2018]. However, 
more recent literature has revealed that a 1,4-BD-induced coma can last longer than 
those due to GHB, with patients recovering more slowly due to more prolonged CNS 
depression [Stefani and Roberts, 2020]. The first case report of confirmed 1,4-BD 
intoxication in Portugal provides additional evidence that 1,4-BD can also induce a 
profound coma [Castro et al., 2019].  
 
7.40. Acute GHBRS toxicity can also cause amnesia, which increases the risk of relapse 
as users do not recall the experience of acute intoxication and overdose [Doyon, 
2001].  
 
Management  
7.41. Current treatment for GHB/GBL overdose is limited to supportive care, as antidotes 
that are available for other substance groups (for example, naloxone and flumazenil) 
have no beneficial effect in the treatment of GHB intoxication [Nunez et al., 2018].  
 
7.42. There is new evidence showing that specific monocarboxylate transporter 1 (MCT1) 
inhibitors enhance GHB renal excretion and reduce respiratory depression after oral 
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GHB or GBL overdose in rats [Follman and Morris, 2019]. This updates previous 
evidence that suggested that MCT1 inhibitors might be useful treatments [Vijay et 
al., 2015] because MCT1 mediates the brain uptake of GHB [Kaupmann et al., 
2003; Goodwin et al., 2005; 2009]. However, this is very early stage research and is 
only likely to be effective if administered one to two hours after GHB/GBL ingestion 
[Follman and Morris, 2019], so is currently (2020) not an approved antidote to GHB 
or GBL overdose.  
 
Long-term toxicity effects  
7.43. Comas have previously been weakly associated with hypoxia (oxygen deprivation) 
and may lead to oxidative stress in the brain [Nayak et al., 2006; Perouansky and 
Hemmings, 2009; Snyder et al., 2017]. Recent evidence shows that in addition to 
the immediate effects of the coma, there are long-term negative effects of GHB-
induced coma on memory [Pereira et al., 2018] and emotional processing [Pereira 
2019a; 2019b].   
 
Gastroenterological symptoms 
 
7.44. Vomiting in acute intoxication is common; literature reports range from 17% to over 
50% of GHB overdoses being accompanied by vomiting [Garrison and Mueller, 
1998; Degenhardt et al., 2002; Wood et al., 2008]. Vomiting in individuals with 
reduced consciousness increases the risk of aspiration), especially when the GCS 
score is less than 8 out of 15. Therefore, aspiration in patients intoxicated with 
GHB/GBL needs to be considered a significant risk, particularly in those with 
reduced consciousness.  
 
In summary, GHB can cause profound unconsciousness and the steep dose-
response curve puts the user at risk of overdose and death. The co-ingestion of 
alcohol, and other depressants such as benzodiazepines, is a significant 
additional risk factor. The high number of GHB emergency department 
presentations in Europe, alongside the fact that GHB use at a population level is 
estimated to be low, may indicate that GHB harms are over-represented in 
hospitals and clinical settings, thus suggesting harm from GHB may be higher 
than other drugs. However, the evidence of both prevalence and emergency 
department presentations is stronger in The Netherlands and London than in 
other regions in Europe where there is an absence of evidence.    
 
 
Withdrawal syndrome (physiological and psychological dependence) 
 
Tolerance, dependence and withdrawal 
7.45. Tolerance to GHB, GBL and 1,4-BD develops, so larger doses are needed over time 
to produce the same psychoactive effects. Therefore, long-term GHB users typically 
take higher doses than naïve users [EMCDDA, 2002]. Users who have developed 
tolerance to GHB report taking larger doses just ‘to normalise’ themselves rather 
than achieve euphoric effects as before [Chew and Fernando, 2004]. The fact that 
tolerance develops suggests that GHB, GBL and 1,4-BD are psychologically and 
physically addictive with high abuse potential [Corkery et al., 2018].  
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7.46. Tolerance and physical dependence can develop when GHBRS are used regularly 
within weeks to months, especially if use is daily [McDaniel and Miotto, 2001; van 
Noorden et al., 2010; 2017]. A distinctive feature of GHBRS is the rapid onset of 
withdrawal symptoms. The short half-life of GHB (around 30 minutes) means those 
with GHB/GBL dependence need to take every few hours, typically between 1 and 4 
hours, to prevent withdrawal symptoms developing [Galloway et al., 1997; Gonzalez 
and Nutt, 2005; Bell and Collins, 2011; Wood et al., 2011; Choudhuri et al., 2013; 
Liechti et al., 2016]. Withdrawal may also occur during recovery from acute 
intoxication (overdose) [Wojtowicz et al., 2008; Bell and Collins, 2011; PHE, 2014; 
Busardò and Jones, 2015].  
 
7.47. All three drugs are considered to have the same withdrawal syndrome [Lingford-
Hughes et al., 2016; Floyd et al., 2018] and it has been observed in individuals with 
dependence for GHB, GHB/GBL co-ingestion, GBL, and 1,4-BD [Catalano et al., 
2001; Wojtowiez et al., 2008; Zvosec et al., 2011; Evans and Sayal, 2012; Corkery 
et al., 2015]. GHBRS withdrawal symptoms have been reported to last between 3 to 
21 days [McDonough et al., 2004; Schep et al., 2012], with a mean of 9 days 
[McDonough et al., 2004].  
 
7.48. Early withdrawal symptoms from GHB typically include tremor, insomnia, confusion, 
nausea and vomiting [Liao et al., 2018]. After 12–48 hours, anxiety, tachycardia, 
hypertension, agitation and hallucinations may develop [Neptune, 2015]. Severe 
withdrawal may include delirium, seizures, psychosis with delusions, autonomic 
instability with tachycardia, and rhabdomyolysis [McDaniel and Miotto, 2001; 
Wojtowicz et al., 2008; Veerman et al., 2010; Ghio et al., 2014; Neptune, 2015; van 
Noorden et al., 2010; 2017;]. Severe withdrawal can be fatal; clinical management is 
supportive. 
 
Pharmacological management of GHB withdrawal (detoxification) 
7.49. Clinical management of GHB/GBL withdrawal (detoxification), presents the following 
specific challenges. 
 
o The onset of the withdrawal is rapid, and the symptoms are life threatening 
[Kamal et al., 2014; Lingford-Hughes et al., 2016]. 
 
o Identification as GHB withdrawal is challenging due to the fast elimination of 
GHB from the body and the overlap of symptoms with other conditions, such 
as alcohol withdrawal [Bell and Collins, 2011; Wood et al., 2011; Busardò and 
Jones, 2015]. 
 
o Lack of awareness in non-specialist healthcare settings, particularly in EDs 
[van Noorden et al., 2009; Lingford-Hughes et al., 2016]. 
 
o Lack of well evidenced, effective pharmacotherapy interventions [Roth and 
Giarman, 1966; Miotto, 2001; Kamal et al., 2017a; Floyd et al., 2018].  
 
7.50. High-dose benzodiazepines, such as diazepam, have been the standard treatment 
employed for detoxification [Bell and Collins, 2011, Kamal et al., 2017a], however 
this treatment is sometimes ineffective as the GHB withdrawal syndrome may be 
resistant to benzodiazepines [McDaniel and Miotto, 2001; Sivilotti et al., 2001; 
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McDonough et al., 2004; LeTourneau et al., 2008; Wojtowicz et al., 2008; Acciani 
and Kao, 2010; de Jong et al., 2012; van Noorden et al., 2014; Kamal et al., 2017a].  
 
7.51. Benzodiazepine-resistant withdrawal needs to be managed in an inpatient setting, 
as patients may require intubation and critical care admission. Benzodiazepine-
resistant withdrawal tends to be treated by either barbiturates or more recently 
pharmaceutical grade GHB or baclofen [Boukje et al., 2017; Kamal et al., 2017a]. 
Whilst baclofen, either in combination with benzodiazepines [LeTourneau et al., 
2008; Bell and Collins, 2011; Kamal et al., 2015a; 2015b; 2015c; Lingford-Hughes et 
al., 2016; Floyd et al., 2018], or more recently as a stand-alone treatment [Habibian 
et al., 2019] offers promising early findings for managing withdrawal, it is currently 
unlicensed for this use and the reported successes are largely case studies or 
anecdotal. Services/individual clinicians prescribing baclofen need to follow local 
processes for using medicines for off-label indications.  
 
7.52. In addition, GHB detoxification is of higher intensity and duration than for other 
substances, with more contacts required and the highest frequency of associated 
hospital admissions [van Noorden et al., 2017].  
 
7.53. In terms of acute presentation for both intoxication and withdrawal, TOXBASE® has 
clear clinical guidelines, which are used by ED (A&E) staff. However, there are no 
specific guidelines for non-acute presentations to support services, such as elective 
detoxification.  
 
Relapse and recovery 
7.54. Amnesia, including retrograde amnesia, is often caused by GHBRS. This means 
people who experience intoxication, overdose or develop withdrawal syndrome may 
recover with no recall of the episode [Miotto et al., 2001]. In a small study 13% of 
participants experienced amnesia with GHB use, and 45% experienced amnesia 
after GBL use [ibid.]. It is thought that amnesia may increase the risk of relapse in 
this situation, as individuals do not remember their overdose, so it does not act as a 
deterrent [Doyon, 2001].  
 
7.55. Relapse rates for GHB dependence have been shown to be particularly high, with a 
69% relapse rate after three months (following DiTiTap® tapering detoxification), 
with relapse occurring immediately after detoxification in 27% [Boukje et al., 2017]. 
A large cohort study showed that, compared with other addictive substances, GHB 
has a two to five times higher re-enrolment rate in addiction treatment [van Noorden 
et al., 2017]. In the van Noorden paper re-enrolment was taken as a sign of relapse, 
however it could also be considered to be evidence of GHB users having greater 
motivation to seek help and undertake detoxification. As re-enrolment signifies that 
the user has both relapsed and then re-sought detoxification, re-enrolment rate is 
considered a reasonable measure of relapse; although it may not be an appropriate 
measure to compare between substances. This was a large study with over 17,000 
patients in Dutch addiction treatment centres between 2008 and 2011, 0.9% of 
whom had GHB dependence (n=596). 
 
7.56. There are some indications that baclofen may be effective in preventing GHB 
relapse, by increasing the likelihood of a patient completing their recovery treatment. 
However more research is needed to assess the safety of baclofen at higher doses. 
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Several baclofen relapse prevention trials are being conducted [Kamal et al., 2015a; 
2015b; 2015c; Lingford-Hughes et al., 2016]. 
 
In conclusion, the harms from GHB withdrawal syndrome are significant and 
sometimes life-threatening. It is considered a particularly severe withdrawal 
syndrome compared with other drugs. Effective clinical management is 
challenging due to the inherently complex syndrome and the intensity of 
detoxification treatment (treatment contacts and duration), making reducing 
harms from GHB withdrawal challenging for clinicians. There is also a high rate of 
relapse reported, and more research is needed to investigate relapse prevention 
treatment.  
 
Polydrug use with GHBRS 
 
7.57. Little information is known about the behaviour of using GHB in combination with 
other drugs, but symptoms have been found to be more severe when GHB is taken 
in combination with other substances of abuse [Giorgetti et al., 2017].  
 
7.58. A study collected data on all patients attending EDs of the Euro-DEN network over a 
12-month period in 2013/14, recording a total of 710 cases of GHB-related 
presentations [EMCDDA, 2015]. Almost 72% consumed GHB/GBL in combination 
with other substances of abuse [Miró et al., 2017]. In comparison with GHB/GBL-
only consumption, patients consuming GHB/GBL with co-intoxicants presented with 
more vomiting and cardiovascular symptoms, a greater need for treatment and a 
longer ED stay [ibid.]. 
 
Alcohol and other CNS depressants 
7.59. Cross tolerance may occur between GHB and alcohol [EMCDDA, 2008] and both 
alcohol and GHB/GBL can cause changes in behaviour and induce aggression 
[Neptune, 2015]. Patients who use alcohol are, like GHB/GBL users, also more 
likely to vomit [Liechti et al., 2006]. 
 
7.60. More recent evidence has shown that coma occurred in 77% of alcohol and GHB 
co-ingestion presentations in Swiss EDs, compared to 62% of non-alcohol users. 
The percentages did not reach statistical significance but were considered to be 
clinically relevant [Liakoni et al., 2016].  
 
7.61. Subsequently alcohol has been shown to be the most common substance 
consumed with GHB/GBL that results in presentation to EDs [Miró et al., 2017]. 
However, it was unclear whether this was due to alcohol causing additional harm, or 
from alcohol often being present in the context of GHB use (for example, in night 
clubs). A subsequent study in 2017 showed that comas occurring when GHB or 
GBL was combined with alcohol were more life threatening because the alcohol 
increased CNS inhibition, resulting in more pronounced respiratory depression, 
hypotension and bradycardia [Madah-Amiri et al., 2017]. This supports previous 
evidence that when GHB/GBL is taken in combination with other drugs (including 
alcohol or stimulants), the duration and depth of coma are greater than when it is 
taken alone, and recovery times are longer [Liechti et al., 2006; Department of 
Health, 2011; Galicia et al., 2011; Neptune, 2015].  
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7.62. More recent literature provides strong evidence that significant caution is needed 
when taking GHB or precursors in combination with other CNS depressants, such 
as alcohol, as it increases risk of death [Corkery et al., 2018].  
 
HIV antiretroviral agents   
7.63. HIV antiretroviral agents in combination with GHBRS is of concern because there is 
evidence to suggest that the drug-drug interactions may increase the risk of 
GHBRS-related toxicity and seizures and may lower adherence to HIV therapy. 
Literature is limited and more research is needed on drug-drug interactions between 
GHB and HIV medication.  
 
7.64. Elimination of GHB from systemic circulation occurs rapidly by oxidation [Lettieri and 
Fung, 1976; Harrington et al., 1999], but animal data suggest that GHB undergoes 
substantial first pass metabolism (when the concentration of the drug is reduced 
before it reaches systemic circulation). First pass metabolism of GHB may involve 
the enzymes CYP2D6 and CYP3A4, however this is not proven. If the first pass 
does involve these enzymes, then administration of GHB alongside CYP3A4 
inhibitors such as the HIV medicines ritonavir and cobicistat, may lead to raised 
concentrations of systemic circulation of GHB and increased toxicity [Neptune, 
2015]. Therefore, HIV doctors should be made aware of this when changing HIV 
medication and advise patients of the potential risks.   
 
7.65. GHB may precipitate seizure-like activity. Therefore, caution should be exercised by 
people living with HIV who have predisposing seizure disorders or opportunistic 
infections that may lower their seizure threshold, when taking GHB [ibid.].  
 
7.66. Some of the side effects of GHBRS include severe nausea, vomiting and 
gastrointestinal tract irritation. These may adversely affect absorption of 
antiretroviral therapy [Romanelli et al., 2003]. There are also concerns about 
adherence to HIV medication while intoxicated, especially during prolonged binges, 
which may have implications for the effectiveness and durability of HIV therapy 
[ibid.]. It should be noted that evidence for this is limited and there have been no 
recent studies conducted.  
 
Erectile treatment/dysfunction drugs 
7.67. Sildenafil (Viagra) is often reported as being used in the context of chemsex. There 
is little evidence of drug-drug interaction between Sildenafil and GHBRS apart from 
one case report, where the individual experienced symptoms such as chest pain, 
headache and shortness of breath not previously experienced with GHB use [Pichini 
et al., 2016]. 
 
In conclusion, the evidence presented in this section, alongside mortality and 
ED data previously discussed, indicates that GHB taken in combination with 
other drugs either results in more severe harms or increases the risk of harm.  
 
Chemsex and men who have sex with men 
 
7.68. The prevalence of chemsex within different countries and different population 
groups is discussed in chapter 6, which highlights that men who have sex with men 
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(MSM) individuals appear to be particularly prevalent users of GHBRS for use in 
chemsex.  
 
7.69. As already discussed, GHBRS use is particularly prevalent amongst MSM 
individuals within a chemsex context. This section relates to the harms experienced 
by this population of users. In general, most evidence in this field is of general 
chemsex drugs, and not specific to GHBRS. This section aims to present the 
evidence that is available for GHBRS-specific chemsex harms. The main harms are 
risk of sexually transmitted infection (STI)/HIV transmission, physical trauma, 
seizures, and being a victim of sexual assault or other crimes.  
 
STI transmission and infections, including HIV and Hepatitis  
7.70. Condomless sex increases the risk of STI/HIV transmission. Chemsex in general 
has a higher association with condomless sex than other sex facilitation drugs (for 
example, ‘Poppers’) [Hibbert, 2019], and there is some evidence that GHBRS use 
means that individuals are less likely to use condoms for anal sex [Bracchi et al., 
2015; Melendez-Torres et al., 2017]. However, other studies report contradictory 
findings, concluding that chemsex drugs have a varied association with condomless 
sex and risk-taking behaviour, and that practices vary amongst individuals who use 
GHBRS [Bourne, 2015a; 2018; Graf et al., 2018]. A higher number of sexual 
partners also increases the risk of STI/HIV transmission. Chemsex drugs have been 
found to facilitate a higher number of different sexual partners, [Bourne et al., 
2015a; Kapitány-Fövény et al., 2015]. Therefore, GHBRS use in a chemsex context 
increases the risk of STI/HIV transmission due to higher levels of condomless sex 
and higher number of sexual partners.  
 
7.71. In addition to STI and HIV transmission, there is also evidence that GHBRS 
increases risk of transmission of: 
• Shigella flexneri, a pathogen that can cause severe dysentery in humans and is 
orofecally transmitted [Gilbart et al., 2015]; and  
• Lymphogranuloma venereum (LGV), an STI caused by a strain of chlamydia. 
There is evidence that LGV is a significant problem amongst MSM, and that co-
infection with HIV and hepatitis C is common [Ward et al., 2007]. It is thought that 
LGV may facilitate HIV transmission [Ward et al., 2007; Macdonald et al., 2014].  
 
Physical trauma 
7.72. Rectal trauma and penile abrasions are associated with GHBRS use in chemsex 
[Bracchi et al.,2015; Bowden-Jones, 2017] due to length of sexual encounter 
[Bourne, 2015a]. 
 
Seizures  
7.73. GHB/GBL may precipitate seizure-like activity in HIV-positive patients with 
predisposing seizure disorder or opportunistic infections that may lower seizure 
threshold [Romanelli et al., 2003].  
 
Sexual assault 
7.74. Whilst MSM who use GHBRS for chemsex do consent to the initial taking of 
GHBRS, the effects of the drugs (drowsiness, reduced consciousness, coma) make 
individuals vulnerable to sexual assault, rape, and administration of further 
substances, which they either may not consent to, or do not have the capacity to 
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consent to due to the effects of GHBRS. Therefore, those who use GHBRS in a 
chemsex setting may be at heightened risk of sexual assault, and the harms 
associated with sexual assault, including psychological harms.  
 
In conclusion, along with the harms associated with GHBRS discussed in this 
chapter, GHBRS use in the context of chemsex has additional associated 
harms. These include STI and HIV transmission and the risks to health these 
pose, rectal and penile trauma, higher risk of seizures amongst HIV positive 
individuals with predisposed seizure disorders or opportunistic infections, 
and the potential for heightened risk of becoming a victim of sexual assault.  
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8. Mental health harms 
 
Intoxication, delirium, psychosis, mood disorders and anxiety   
 
8.1. A study conducting interviews with 146 gamma-hydroxybutyric acid (GHB) users in 
The Netherlands found that of those who had ‘abundant’ GHB experience (more 
than 200 lifetime episodes of GHB use, n=73), a significant minority deliberately 
sought near-comatose levels of intoxication on a regular basis to sleep or find self-
medicated relief from mental health troubles [Grund et al., 2018].  
 
8.2. Regular use of GHB has been associated with persistent alterations in emotion 
identification, decreased social interaction, and increased social anxiety [van 
Nieuwenhuijzen et al., 2010; Johansson, 2012; Dijkstra et al., 2017]. These are 
negative effects regulated by a major affective network, where the amygdala and 
the hippocampus are central processing hubs [Adolphs 2002, Chudasama et al., 
2009]. Animal studies show that these are regions particularly sensitive to 
neurotoxic effects induced by GHB [van Nieuwenhuijzen et al., 2010; Johansson 
2012]. The most recent evidence of self-reported data in humans combined with 
functional magnetic resonance imaging (fMRI) showed that long-term exposure to 
GHB – particularly GHB-induced coma – has a negative effect on an individual’s 
ability to regulate their emotions [Pereira et al., 2019a; 2019b]. The study found that 
those who had experienced GHB coma reported higher levels of depression, anxiety 
and stress [Pereira et al., 2019b]. All GHB users showed decreased functional 
connectivity in the fMRI data between the hippocampus and the amygdala in 
comparison with the non-GHB group, suggesting that chronic GHB use is 
associated with altered emotional identification and regulation [Pereira et al., 2019a; 
2019b].  
 
8.3. GHB and related substances (GHBRS) use within the chemsex context may have 
additional mental health harms. As part of the Chemsex Study in 2014, some men 
reported problems relating to paranoia, anxiety or aggression, and a few 
experienced acute attacks of mania or psychotic episodes that required medical 
intervention [Bourne et al., 2014]. In addition, the high rates of blackout and coma 
with GHBRS mean, taken within a chemsex contact, an individual may be less able 
to give consent. Within the context of a chemsex study, 3 out of 30 men reported 
being a victim of non-consensual sex [Bourne, 2015a; 2015b]. Another study found 
17% of participants reported loss of consciousness during sex and 6% reported their 
partner losing consciousness during sex [Glynn et al., 2017]. In addition to physical 
harms, there is also significant psychological distress from this type of sexual 
assault [Bowden-Jones, 2017].   
 
Memory disorder 
 
8.4. Human studies assessing the regular use of GHB have suggested a link between 
regular GHB use and reported memory complaints [Barker et al., 2007; Durgahee et 
al., 2014]. However, until recently there has been no strong neurological evidence in 
human studies of the long-term effects of GHB use on memory.  
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8.5. New evidence has demonstrated an association between repeated GHB-induced 
comas and the negative effect on associative long-term memory processing and 
performance [Pereira et al., 2018]. The study conducted neuroimaging on three 
different user groups (regular GHB users with four or more coma episodes, GHB 
use with no coma episodes, non-GHB polydrug users) during verbal and spatial 
memory encoding tests. The results of the tests alongside fMRI data showed that 
the group of GHB users with four or more coma episodes performed worse on the 
verbal recognition memory test and recruited sections of the brain associated with 
memory (primarily the hippocampus) less during the memory encoding test than the 
other two groups [Pereira et al., 2019a; 2019b]. This is the first evidence of the 
effects of GHB use on memory and is considered reasonably robust evidence due 
to the control groups and neuroimaging data.  
 
Intensity of withdrawal on cessation of drug use  
 
8.6. As discussed in chapter 7, the withdrawal from GHBRS on cessation is severe. 
Withdrawal from recreational or medical use of GHB is often associated with 
anxiety, stress, and sporadically depression [Johansson, 2012; Dijkstra et al., 2017; 
Kamal et al., 2017b; Miró et al., 2017; UN Office on Drugs and Crime, 2017].  
 
8.7. Mental health problems and cognitive disabilities are reportedly widespread among 
people who use GHB during and after treatment [Dijkstra et al., 2013; Beurmanjer et 
al., 2018]. Among people in treatment for GHB dependence, 74% to 96% reported 
sleep disturbances [Dijkstra et al., 2013; Beurmanjer et al., 2018; Grund et al., 
2018]. A Dutch study of 98 patients undergoing GHB detoxification monitoring 
showed a high rate of psychiatric co-morbidity (79%), which included anxiety, mood 
and psychiatric disorders [Kamal et al., 2017b]. The level of psychological distress 
was significantly higher than the standard outpatient reference group. The paper 
concludes that GHB dependence is characterised by serious psychiatric comorbidity 
and psychological distress, both of which are associated with increased GHB use – 
creating a cycle leading to lower quality of life [ibid.].  
 
In conclusion, there is a strong base of new evidence about the mental health 
harms caused by GHBRS since the Advisory Council on the Misuse of Drugs 
last considered their harms.  
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9. Social harms 
 
Crimes facilitated by GHBRS  
 
9.1. Crime was not part of any previous Advisory Council on the Misuse of Drugs 
(ACMD) considerations on gamma-hydroxybutyric acid and related substances 
(GHBRS). Therefore, all evidence in this chapter is evidence of new harms.  
 
9.2. The table below summarises the number of different types of offences committed for 
both GHB and gamma-butyrolactone (GBL) in England and Wales in the last five 
years (2015 to 2020). The table shows that the majority of offences are for 
possession of a controlled drug (72% of offences).  
 
Table 4: Number and type of offences committed relating to GHB and 
 GBL, 2015–2020  
Number of offences 
Total offences (2015–20) 
GHB GBL Combined total 
Production of or being concerned in 
the production of a controlled drug  
1  1 
Supplying or offering to supply (or 
being concerned in supplying or 
offering to supply) a controlled drug 
13 37 50 
Having possession of a controlled 
drug  
110 37 147 
Having possession of a controlled 
drug with intent to supply 
3 4 7 
Grand total 127 78 205 
Note: Home Office data for GHB are as of September 2019. (Data supplied 
from the Home Office Data Hub as of 25 March 2020. Data are provided by 
38 police forces in England and Wales. Data have not been reconciled by the 
police forces). 
 
9.3. The Metropolitan Police Service (MPS) has indicated significant concern about the 
emerging nature of offending behaviour within the chemsex context, and the 
weaponisation of ‘chems’ – crystal methamphetamine, mephedrone, GHB/GBL. The 
MPS has reported particular concern about GHB/GBL, as they are considered the 
most dangerous of these three substances to an individual [Metropolitan Police, 
2020a]. The MPS also notes that the supply of GHB/GBL attracts the involvement of 
organised criminal networks [Metropolitan Police, 2020a; 2020b].  
 
9.4. In the UK in recent years, GHBRS have been used to facilitate serious crimes, 
including murder, rape, sexual assault and robbery. Some of these crimes occur in a 
chemsex context, however this is not exclusively the case. A number of criminal UK 
cases are outlined below and demonstrate the extreme harm that can be inflicted on 
others by predators using GHBRS. 
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Murder 
 
9.5. The cases of Stephen Port and Gerald Matovu outlined below provide evidence of 
GHBRS being used as a murder weapon.  
 
Stephen Port – four counts of murder and rape 
9.6. Stephen Port, 41 years old, was found guilty in 2016 of four counts of murder; ten 
counts of administering a substance with intent; four counts of rape; and four counts 
of assault by penetration [Pettigrew, 2018; Crown Prosecution Service, 2019]. He 
often met his victims, all young men, using dating websites and apps and inviting 
them to his house. There he surreptitiously administered GHB in its liquid form with 
the aim of raping them whilst in a comatose state. Four men died as a result of the 
GHB administration and the bodies were found in or near a graveyard close to 
Stephen Port’s house [Pettigrew, 2018]. 
 
Gerald Matovu 
9.7. Gerald Matovu, age 25 years, drugged men with GHB and stole from them after 
meeting them for sex through dating apps such as Grindr. In total there were seven 
victims of theft, five of whom he drugged with GHB in order to steal from them. He 
administered a lethal overdose to one of the five men, Eric Michels, and was 
convicted of murder in July 2019 [Crown Prosecution Service, 2019]. Before Mr 
Michels’ death, Matovu had been convicted of supplying GHB to serial killer 
Stephen Port (above) and was aware of the danger of GHB doses. Matovu and 
Brandon Dunbar, a man he sometimes worked with to contact men on Grindr and 
steal from them and/or assault them, have not yet been sentenced [ibid.].  
 
Drug-facilitated sexual assaults  
 
9.8. Drug-facilitated sexual assault (DFSA) is where a victim is unable to give or rescind 
sexual consent due to intoxication that is either self-administered or covertly 
administered by the perpetrator (predatory DFSA) [UN Office on Drugs and Crime, 
2011]. 
 
9.9. It is suggested that only 15% of all sexual assault victims (including DFSA) in 
England and Wales report it to the police [Ministry of Justice, Home Office and the 
ONS, 2013]. Victims cite feelings of shame, embarrassment, guilt, fear and denial 
as reasons for not reporting sexual crimes [ibid.; Grela et al., 2018; Busardò et al., 
2019; Paul et al., 2019]. Of the sexual assaults that are reported, the proportion that 
are drug-facilitated is difficult to estimate.  
 
9.10. When identifying the drugs used in DFSA, consistently reported as the most 
common is alcohol [Bertol et al., 2018; Grela et al., 2018; Busardò et al., 2019]. 
Aside from alcohol, some studies report DFSA to be most common with 
flunitrazepam and GHB [Marinetti and Montgomery, 2010; Busardò et al., 2019; 
Veerman et al., 2019] due to their properties of causing retrograde amnesia, 
sedation, ease to dissolve in drinks, rapid onset of action, and rapid elimination from 
the body. One study commented that GHB is one of the most commonly used 
substances in DFSA [Bracchi et al., 2015] and another found GHB to be five times 
more prevalent than flunitrazepam in sexual assault [White, 2017]. However, a 
number of other studies contradict this and show the prevalence of GHBRS DFSA 
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to be low. A systemic review from 2010 reporting the rate of GHB-positive samples 
among victims of reported sexual assault to be between 0.2% and 4.4% [Németh et 
al., 2010], showing relatively low prevalence. This was supported by a study in Italy 
where 256 sexual assaults between 2010 and 2018 were analysed to find there was 
only one confirmed case of GHB being used to facilitate the sexual assault [Bertol et 
al., 2018]. This low prevalence was also confirmed by a study in Hungary, which 
collected questionnaire responses from 60 GHB users about their GHB use in a 
sexual context, with 2 subjects reporting sexual assault (3.4%) [Kapitány-Fövény et 
al., 2015]. Due to fast elimination from the body and no common protocol for data 
collection (including samples collected, drugs routinely tested for, and methods of 
analysis), there is no accurate evidence on prevalence of DFSA or date rape under 
the influence of GHBRS, which may explain why literature on DFSA varies.  
 
9.11. Whilst some research suggests that the frequency of GHB facilitated sexual 
assaults are over-estimated and recommends the term ‘alleged sexual assault’ 
[ElSohly and Salamone, 1999; Varela et al., 2004; du Mont et al., 2010; Németh et 
al., 2010], the theme in more recent literature is that GHBRS DFSA is under-
reported [Grela et al., 2018; Paul and Mahesan, 2019]. This is because sexual 
assault in general is:  
• under-reported;  
• forensic testing is needed to identify any drugs, which is challenging 
retrospectively; and 
• because victims often do not report the assault, and if it is reported it is not often 
reported immediately.  
 
9.12. These last two factors are particularly problematic for GHBRS DFSA. GHB causes 
retrograde amnesia so victims often have large gaps in their memory, sometimes 
not knowing they have been assaulted when they awake from their sedated state, 
meaning they are less likely to report the attack. Even if the victim does report the 
attack, due to GHB being eliminated from the body very quickly, by the time the 
victim’s sample is collected, the drug is likely to have been metabolised, making it 
undetectable in forensic analysis [Scharf, 1998; Borgen et al., 2003; Abanades et 
al., 2006; Grela et al., 2018; Busardò et al., 2019]. It is widely accepted that the 
presence of exogenous GHB is difficult for forensic toxicologists to confirm 
[Brailsford et al., 2012] and it is not always tested for. For these reasons, it can be 
reasonably concluded that GHB-facilitated DFSA is under-reported [Bertol et al., 
2018].  
 
9.13. GBL has a faster onset of action than GHB [Wood et al., 2008; Busardò and Jones 
2015; Veerman et al., 2019], theoretically making it a better candidate for 
premeditated DFSA. A recent review concludes that due to GBL having a less 
restricted legal status than GHB, a low cost, and being readily available to buy on 
the internet, this has led to GBL being the preferred DFSA drug over GHB [Veerman 
et al., 2019].  
 
9.14. A number of GHBRS suspected DFSA crimes are outlined below.  
 
Reynhard Sinaga, UK – 159 counts of sexual offences, 136 counts of anal rape 
9.15. In January 2020 Reynhard Sinaga, age 36 years, was found guilty and jailed for life 
after drugging and assaulting 48 identified men between 2015 and 2017. He was 
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found guilty of 159 sexual offences, including 136 condomless anal rapes. He has 
been described as Britain’s most prolific rapist in history [Crown Prosecution 
Service, 2020]. Sinaga approached intoxicated young men in central Manchester 
and lured them back to his flat near the city’s nightclubs, on the pretence of having a 
drink or ordering a taxi. There, Sinaga spiked his victims’ drinks with sedatives, 
primarily suspected of using GHBRS, to make them unconscious. After that he 
filmed himself raping them [ibid.]. Although GHBRS was never forensically 
confirmed (due to its fast elimination from the body), it is suspected Sinaga used 
GHB or similar due to the observed presentation of victims in the video footage (for 
example, coma and vomiting). The Crown Prosecutor commented that the victims 
“have suffered severe and life-changing psychological trauma”. This case provides 
strong evidence that GHBRS can and is used as a weapon for sexual assault in the 
UK, and demonstrated the severe harm caused to victims. 
 
DFSA crimes involving 1,4-BD and GHV/GVL 
9.16. Early evidence in the USA, from 2002, reported a man drugging his wife and their 
babysitter and sexually abusing them both, reported by the National Drug 
Intelligence Centre (NDIC). He added 1,4-butanediol (1,4-BD) to their drinks in order 
to drug them to facilitate the sexual assault [US Department of Justice, 2002]. This 
shows that even in 2002, 1,4-BD was being used in the same way as GHB/GBL to 
facilitate sexual assault.  
 
9.17. Gamma-hydroxyvaleric acid/gamma-valerolactone (GHV/GVL) have been 
associated with (but not analytically confirmed) in one case of DFSA [Andresen-
Streichert et al., 2013]. 
 
Acquisitive crimes 
 
9.18. As mentioned previously, the high rate of blackout amongst GHB users makes them 
vulnerable and susceptible to crime. In addition to DFSA, other criminal activity is 
also facilitated by GHB. There is emerging evidence that GHB facilitates acquisitive 
crimes. Acquisitive crimes are when an individual takes (acquires) something from 
another individual – also referred to as robbery or theft.  
 
9.19. A Hungarian study that reported two cases of DFSA amongst the 60 participants 
(3.4%), also found that 5 participants reported acquisitive crimes (8.6%) [Kapitány-
Fövény et al., 2015]. A further study conducted by the same researchers considered 
408 GHB intoxication cases and compared whether crimes were committed against 
the individuals, and how they came to ingest GHB (unintentionally or intentionally). 
Those who took GHB intentionally had no crimes committed against them; it was 
only people who took GHB unintentionally (although there may be self-reporting 
bias) who reported having crimes committed against them (ibid.). This suggests that 
GHB is used as an instrument in crime. The study concluded that of the total 408 
GHB intoxications they reviewed, acquisitive crimes were committed against the 
individual in 38 cases (9.6%). In comparison, GHB sexual assault happened in 11 
cases (2.8%) [Kapitány-Fövény 2017]. This is consistent with the previous smaller 
study in terms of prevalence of both acquisitive crime and DFSA.  
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9.20. These two papers were the first to provide evidence of acquisitive crimes facilitated 
by GHB and demonstrate that GHB facilitates acquisitive crimes more frequently 
than it facilitates DFSA [Kapitány-Fövény et al., 2015; 2017].  
 
9.21. The Gerald Matovu case described earlier in this chapter also highlights the use of 
GHB and its analogues in robbery, with the potential for even more serious harms, 
including death [Crown Prosecution Service, 2019].  
 
Personal relationships  
 
9.22. Five gay men and two straight women described using GHBRS daily for over a year, 
and for some over a two- to three-year period, as part of a small but in-depth 
qualitative study. Because of problematic use of GHB, the participants referred to 
changes in perceptions of their identity, and loss of connectivity to family, 
community and work roles [Joyce et al., 2013]. 
 
9.23. There is consistent evidence that that GHBRS use is associated with isolation and 
loneliness [Joyce et al., 2013; Zapata, 2013; Bourne, 2015a; Pollard et al., 2018; 
Evers et al., 2020]. Whilst chemsex is frequently reported as a driver behind initial 
GHBRS use, once the individual becomes dependent and uses daily, chemsex was 
no longer a significant feature and the individual generally became withdrawn from 
previous social settings and communities [Stuart, 2013a; Zapata, 2013; Joyce et al., 
2018]. 
 
Stigmatisation 
 
9.24. Stigma is widely experienced by drug users from all communities, and those who 
use GHBRS within the lesbian, gay, bisexual and trans-gender (LGBT) community 
have reported multiple stigma, discriminations and oppressions [Lea et al., 2013; 
Ahmed et al., 2016]. Stigma related to use of GHB is widespread thus potentially 
leading to patterns of use that are ‘hidden’, difficult to detect, and not open to 
preventative or intervention approaches. 
 
9.25. The stigma surrounding GHB/GBL use has been attributed in part to community 
members’ knowledge of the high incidence of overdose and adverse effects of the 
drugs [Palamar and Halkitis, 2006]. In Canada, anti-GHB campaigns in the nightclub 
scene have commenced in response to recent overdoses [Palamar, 2018]. 
However, while stigma might divert people away from using GHBRS, it may lead 
others to hiding their use and thereby increasing risk.  
 
9.26. A further level of ‘in group’ stigma is demarcated by how the drug is administered, 
with injecting drugs users who ‘slam’ or inject being perceived as taking greater 
risks than those who ingest GHB or related drugs orally [Ahmed et al., 2016]. 
 
9.27. High-profile cases that involve the use of GHBRS in sexual assault, such as the 
trials of Port and Sinaga outlined earlier in this chapter, can have a negative effect 
on the gay and bisexual men as a community. This is because negative press linked 
to a group of people can cement stigma and homophobia, which is likely to increase 
shame for these men. This can be a major barrier to accessing substance misuse, 
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sexual health, and mental health support that they could benefit from [LGBT 
Foundation, 2020].  
 
9.28. LGBT and men who have sex with men (MSM) groups have also reported perceived 
judgement of their sexualised chemsex behaviour by the health services [UK Drug 
Policy Commission, 2010], creating a major barrier to service access.  
 
GHBRS impaired driving 
 
9.29. A study was conducted with 51 current and past users of GHB who were asked 
about their decision making and experiences of driving under the influence of GHB. 
The symptoms that most commonly caused driving difficulties were rapid loss of 
consciousness, onset of stupor, and ante-retrograde amnesia [Barker and Karsoho, 
2008]. There was consensus among participants that driving after taking GHB was 
risky and unsafe and could lead to injuries. Nevertheless, a minority (16%) of 
participants reported first-hand experience of driving under the influence of GHB 
[ibid.].  
 
9.30. This has been supported by more recent studies, which found that GHB causes 
cognitive and psychomotor impairment and risky driving behaviour [Centola et al., 
2018; Darke et al., 2020], with severe impairment observed in real cases of driving 
under the influence of GHB. In addition, a case report from Taiwan reports several 
traffic accidents caused from driving under the influence of GHB [Liao et al., 2018].  
 
9.31. Analysis for GHB was performed on samples collected from motor vehicle drivers in 
Australia from 2011 to 2018. Of the 15,000 blood samples collected, GHB was 
identified in 1.1% of them (n=160) [Griffiths and Hadley, 2019]. A significant finding 
in the study was that GHB was very commonly co-consumed with amphetamine-
type substances (91%). This study provides the first evidence of the prevalence of 
GHB intoxication amongst motor vehicle drivers. However, it did not draw any 
conclusions on how this may relate to driving accidents.  
 
Other  
9.32. Adverse effects on employment were not widely acknowledged in the relevant 
literature, although [Bourne et al., 2015a; 2015b] posited that withdrawal negatively 
influenced work attendance and focus, which ultimately had a negative effect on 
work performance.  
 
9.33. The LGBT Foundation has also provided unpublished anecdotal evidence of 
GHBRS use leading to severe social harms, including homelessness.  
 
In conclusion, there is strong new evidence of significant criminal harm from 
GHBRS, including murder, DFSA and robbery. Other evidence of social harms 
is sparse, but the evidence available suggests a reduction or loss of an 
individual’s social and community networks, and a negative impact on 
personal relationships. There is significant evidence of stigma experienced by 
LGBT GHBRS users, which is a barrier to service access. There is a scarcity 
of information as regards the effects of GHBRS on employment, family life, 
education and housing. 
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DFSA victim support 
 
9.34. Although most of this chapter relates to drug-facilitated sexual assault (DFSA) 
harms in general, as evidenced in chapter 9, gamma-hydroxybutyric acid and 
related substances (GHBRS) have been found to be used in DFSA crimes.  
 
9.35. The support interventions available in the UK for individuals who experience sexual 
assault are outlined below. 
• Rape and Serious Sexual Offences (RASSO) services provide a range of support 
for victims/survivors of sexual violation, ranging from peer-led interventions, 
group work, talking therapy and independent sexual violence advisors (ISVAs) all 
with the aim of supporting the individual to work through the psychological impact 
of the unwanted sexual experiences.  
• The National Institute for Care and Excellence (NICE) recommends that trauma-
focused cognitive behavioural therapy (CBT) and eye movement desensitisation 
and reprocessing (EMDR) are used to treat post-traumatic stress disorder 
(PTSD) [NICE, 2018], which is a key impact of DFSA. However, the guidelines 
are focused on single incident trauma and the treatment conducted within one 
month of the incident. As victims of sexual assault often take years to disclose, 
treatment should be thought about in a wider context and focused on trauma and 
recovery [Herman, 2015].  
• All individuals seeking support should be offered the opportunity to be assessed 
by an ISVA [Home Office, 2017] to ensure that the victim understands the options 
available to them and give them a ‘care co-ordinator’, particularly if engaging in 
the criminal justice system and investigation process. 
 
9.36. RASSO services, and specialist provision from the voluntary, community and social 
enterprise (VCSE) sector, has historically, and continues to, mainly provide support 
to women and girls, as discussed at the Women and Equalities Committee on Boys 
and Men [Parliament UK, Commons Select Committee, 2019].  
 
9.37. Whilst RASSO services have had an awareness of the actuality of DFSA [ElSohly 
and Salamone, 1999] the focus has been on a binary view of female victims of male 
perpetrated crimes and held under the umbrella of violence against women and girls 
(VAWG) [Home Office, 2016]. In March 2019, the Government published the first 
position statement on male victims of crimes considered VAWG [Ministry of Justice, 
2019]. This gave formal visibility to male victims of sexual violence and highlighted 
the need to provide specialist quality services for males [Rape Crisis England and 
Wales, 2018] with the advent of the male quality standards [Male Survivors 
Partnerships, 2018]. In addition, whilst men who have sex with men (MSM) who use 
GHBRS for chemsex do consent to the initial taking of GHBRS, they may become 
vulnerable to additional sexual or substance abuse that they may not be capable of 
giving or rescinding consent for due to the effects of GHBRS, as discussed in 
chapter 7. It is vital that men can access specialist RASSO services and medical 
support, whether in relation to DFSA or chemsex-related harms. It is also vital they 
can have both practical assistance from an ISVA, and from mental health 
professionals who understand the impact of sexual violence.  
 
9.38. During the Stephen Port trial (see 9.6 above), some victims experienced a fear of 
reporting crimes to the police for fear of prosecution in relation to GHBRS use. It is 
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important that users are encouraged that should they become a victim of sexual 
assault, they should report a crime to the police, although fear of prosecution could 
be a barrier for sexual assault victims to come forward. The Greater Manchester 
Police ran an effective community engagement exercise encouraging individuals to 
come forward and report sexual assault following the Sinaga case.  
 
9.39. As the provision of specialist sexual violence services is weighted to supporting 
females, the understanding of DFSA is equally weighted towards female victims, 
which sets a precedent to a complex set of barriers that prevent male/trans victims 
from seeking support and thus, denies further understanding of the actual 
phenomena of DFSA.  
 
9.40. However, as the 2020 Reynhard Sinaga case was identified as the ‘biggest rape 
case in British legal history’ [Crown Prosecution Service, 2020] it thrust male victims 
of DFSA into the spotlight with a vast amount of media interest and reporting [BBC 
News, 2020a; 2020b; ITV News, 2020; the Guardian, 2020a; 2020b; Victoria 
Derbyshire, 2020]. This led to an increase in contacts to victim support services and 
alongside it an increase in government funding for specialist support services 
[Ministry of Justice, 2020].  
 
In conclusion, both men and women experience significant harm from DFSA. 
However, there are currently (as at 2020) more barriers to men accessing 
support interventions available. In addition, the provision of specialist 
services is weighted towards supporting female victims, meaning that support 
for male victims of DFSA, and particularly males who experience harms from 
chemsex due to decreased ability to provide consent, is not well recognised 
or developed nationally.  
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10. Conclusions and recommendations 
 
The Advisory Council on the Misuse of Drugs (ACMD) advises that the following 
recommendations be considered by the Government as a package of interventions. No 
single recommendation among them will be sufficient to significantly reduce the harms 
associated with gamma-hydroxybutyric acid and related substances (GHBRS) use.  
 
Due to the significant risk of harm from overdose and withdrawal, alongside new 
evidence of mental health harms and harms from DFSA crimes, and the specific needs 
of GHBRS users, recommendations 5, 6 and 7 relate to improving treatment services for 
GHBRS overdose, withdrawal, dependency, mental health and sexual health. 
Recommendation 9 focuses on preventing harm coming to GHBRS users by improving 
their understanding and awareness of the potential harms of GHRBS use.  
 
 
Monitoring: surveillance and data 
 
10.1. It is estimated that overall use of GHBRS in the UK, and in each devolved 
administration, is low – with more evidence of use in England than in the other 
devolved nations. There is consensus across the literature that there was a steep 
increase in GHBRS use in the UK, specifically in England, from 2005 to 2015. Since 
2015 the evidence suggests a plateauing in use; albeit with a small and steady 
pattern of use and harm. However, prevalence estimates are challenging in the 
absence of general population data in the UK, and with no systematic data 
collection. There is also a likely underestimate of harm due to the fast elimination of 
GHBRS from the body and subsequent difficulties identifying GHBRS in:  
• post-mortem samples;  
• emergency department (ED) admissions;  
• sexual health and drug misuse services; and  
• criminal investigations.  
 
10.2. Therefore, there is a need to develop systems for future monitoring of the 
prevalence of GHBRS use and the harms they cause.  
 
10.3. The 2019 British Association for Sexual Health and HIV (BASHH) guidelines on 
sexual history taking now recommend obtaining a history of recreational drug use 
(including alcohol and chemsex) for all attendees when taking a sexual history 
[BASHH, 2019]. The Genitourinary Medicine Clinic Activity Dataset (GUMCAD V3), 
is the updated version of the mandatory data reporting by sexual health services to 
Public Health England (PHE). This new version is currently (2020) being rolled out 
across England and includes new data fields for drug use and chemsex. Therefore, 
ensuring that sexual health services can action the GUMCAD V3 data collection by 
providing IT updates or required funding, could improve data collection on GHBRS 
use. The recommendation here is to ensure that sexual health services respond to 
the GUMCAD V3 update.  
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10.4. There is a concern stemming from anecdotal clinician reporting of emerging and 
increasing use of GHBRS as a recreational club drug, and in other groups who use 
it outside of a sexual context. Therefore it is important to consider and monitor these 
trends.  
 
Recommendation 1: Data collection and reporting  
To improve current service level data collection and reporting in the following ways: 
Part 1 
• Ensure that sexual health services report relevant sections as required in GUMCAD 
V3, with financial support afforded to those services that require adaptation of 
electronic patient systems. 
 
• For the PHE National Drug Treatment Monitoring System (NDTMS): 
a) service reporting of sexual orientation to remain above 95% field completion; 
and  
b) to make publicly available, on an annual basis, the sexual orientation for 
individuals in treatment for GHBRS, crystal methamphetamine, ketamine and 
mephedrone (note: all four relevant chemsex drugs are included to give an 
indication of chemsex needs and ensure that data for GHBRS does not need to 
be limited by PHE for the reasons of disclosure control).  
 
• Part 2 
For the Crime Survey for England and Wales (CSEW) to collect data frequently from 
all individuals on:  
a) GHBRS use; and 
b) sexual orientation. 
 
• Part 3  
For the UK Government to provide sufficient funding to enable provision and analysis 
of The Gay Men’s Sex Survey (GMSS) for at least five years. As this has previously 
been funded as part of an EU grant this recommendation is in line with the UK 
Government’s commitment that research in the UK will not suffer as a result of EU-
exit.  
 
Lead organisations:  
Part 1: PHE; the Home Office; and British Association for Sexual Health and HIV 
(BASHH).  
Part 2: The Home Office; and the Office for National Statistics.  
Part 3: UK Government department responsible for funding research. 
 
Measure of impact: 
Part 1 of recommendation: 
• for 95% reporting from all services in NDTMS;  
• at least 65% improvement in services reporting via GUMCAD V3; and  
• evidence of financial support where services require it.  
Part 2 of recommendation:  
• CSEW survey: For subsequent CSEW survey reports to demonstrate that the 
question has been asked and data have been collected, and that there is 
improvement in the data completeness over time.  
Part 3 of recommendation:  
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• GMSS: For confirmed funding of the GMSS survey for at least the next five 
years.   
 
Toxicology 
 
10.5. There is evidence of increasing mortality associated with GHBRS use since the 
ACMD last considered harms of GHB in 2003, and gamma-butyrolactone (GBL) and 
1,4-butanediol (1,4-BD) in 2008. Although the overall number of deaths is relatively 
low there was a particularly steep rise in deaths between 2008 and 2015. There is 
more recent evidence that GHBRS have a higher risk of fatality when GHBRS 
mortality is compared with novel psychoactive substances (NPS) drugs. However, 
mortality figures are likely to be an underestimate due to the challenges in testing for 
and identifying GHBRS in post-mortem samples, due to both rapid elimination and 
endogenous GHB production post-mortem. Mandatory testing for GHBRS in cases 
of unexplained death would improve data on GHBRS mortality. Although there are 
several reasons why testing for GHBRS may not be possible or appropriate in all 
cases of unexplained death, a statement to the effect of why it has not been done, 
or the result of the test, would improve data on mortality associated with GHBRS. 
 
Recommendation 2: Testing  
Testing for GHBRS should be routinely undertaken in all cases of unexplained sudden 
death. Where testing is not possible (for example, not enough sample, financial, or other 
reason) then a clear statement should be included in the toxicology report stating that  
GHBRS testing has not been carried out. Where a blood sample is positive for GHBRS, 
if possible, this should be confirmed in another sample type, for example, urine.  
 
Lead organisations:  Forensic services; sexual assault referral centres (SARCs); 
coroners in England, Wales and Northern Ireland; and procurators fiscal in Scotland.  
 
Measure of impact: Non-systematic toxicology screening for GHBRS hinders the 
capacity to measure and understand trends in GHB use and harm. If these 
recommendations are implemented, those agencies and researchers monitoring GHBRS 
involvements in deaths, will be able to report GHBRS-related deaths as a proportion of 
those tested for GHBRS. In cases of unexplained sudden death, impact could be 
measured with testing (numerator) and autopsies (denominator).  
 
Enforcement 
  
Classification of GHBRS under the Misuse of Drugs Act 1971 (MDA)  
 
• GHB, GBL and 1,4-BD are currently in Class C 
• Gamma-hydroxyvaleric acid (GHV)/ gamma-valerolactone (GVL) are 
currently uncontrolled 
 
10.6. GBL and 1,4-BD are pro-drugs for GHB and have a similarly steep dose-response 
curve as GHB, meaning their physical and psychoactive effects are very similar to 
GHB. Although there was some evidence to suggest that GBL was slightly more 
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potent than GHB, the harms associated with GHB, GBL and 1,4-BD were broadly 
comparable – meaning that it would be appropriate to classify all three under the 
same class of the MDA. 
 
10.7. There is increasing evidence of physical, mental and social health harms related to 
GHBRS. Of particular note are the new harms identified since the ACMD last 
considered GHBRS - severe harm from crimes facilitated by GHBRS and mental 
health harms associated with GHBRS use.  
 
10.8. There is limited evidence of harms and prevalence of GHV and GVL misuse and 
therefore the control of these compounds under the MDA at this time is not 
recommended. These compounds should be monitored by the ACMD and 
considered subsequently for control, should evidence emerge of associated harms 
or increased prevalence of use due to a shift towards these substances as a result 
of the recommended re-classification of GHB, GBL and 1,4-BD. 
 
 
Recommendation 3: Classification  
The ACMD recommends that GHB, GBL and 1,4-BD be moved to Class B of the MDA.  
 
Lead Department: The Home Office. 
 
Measure of implementation: Legislative change to the MDA. This recommendation should 
be considered alongside recommendations 5 to 8, which will collectively provide a range of 
interventions to reduce the harms associated with these compounds.  
 
Metrics for assessing the intended effect: Reduction in severe harm from crimes 
facilitated by GHBRS and mental health harms associated with GHBRS use 
 
There may be unintended effects of the recommendation (see discussion in Annex E). 
These might be quantified and gaps in evidence could be explored further with research.   
 
Scheduling of GHBRS under the Misuse of Drugs Regulations 2001 (MDR) 
 
• GHB is currently in Schedule 2 of the Misuse of Drugs Regulations 2001 
• GBL and 1,4-BD are currently unscheduled in the Misuse of Drugs Regulations 2001 
and are in Part 1, Schedule 1 of the Misuse of Drugs (Designation) (England, Wales 
and Scotland) Order 2015 
 
10.9. The ACMD’s 2013 advice relating to the scheduling of GHB remained current in 
2020. The legitimate therapeutic use of GHB (in the GHB-based drug for 
narcolepsy, Xyrem) means that it would be inappropriate to place GHB in Schedule 
1 of the MDR, whilst keeping GHB in Schedule 2 of the MDR would ensure that the 
relevant requirements are applied to GHB, as a Schedule II drug under the 
Convention on Psychotropic Substances of 1971, under UK legislation. 
 
10.10. A range of options for scheduling GBL and 1,4-BD have been considered, as 
outlined in Annex E, balancing the restriction of the illegitimate supply of these 
compounds with a consideration of the legitimate large volume use of these 
compounds by the chemical industry.  
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10.11. There is a need to disrupt the unrestricted sale from suppliers of GBL and 1,4-BD on 
the open-web purporting to be ‘cleaning materials’ when clearly destined for the illicit 
market. While a licensing regime would ‘catch out’ illegitimate suppliers, large-scale 
legitimate chemical suppliers would most likely be able to adapt to the imposition of 
a licensing regime for GBL and 1,4-BD. There is limited prevalence of the utilisation 
of GBL and 1,4-BD among the UK chemical industry, and there is an existing 
framework (the controlled drug licensing regime) that can be used to control GBL 
and 1,4-BD. Additional controls could also mitigate the risk of diversion of GBL/1,4-
BD from the chemical industry to the illicit market. Given the large volumes (multiple 
litres) that can often not be accounted for by the chemical industry, there is an 
argument that regulatory oversight could be beneficial in these settings.  
 
10.12. As the ACMD is not recommending the control of GHV and GVL under the Misuse 
of Drugs Act 1971 at this time, GHV and GVL will not need to be scheduled under 
the Misuse of Drugs Regulations 2001.  
 
Recommendation 4: Scheduling  
The ACMD recommends that:  
i) GHB remains scheduled under Schedule 2 of the MDR (as amended). 
ii) GBL and 1,4-BD are placed under Schedule 1 of the MDR (as amended), and that their 
legitimate industrial uses are made subject to a Home Office controlled drugs licensing 
regime. 
 
Lead Department: The Home Office. 
 
Measure of impact: Legislative change to the MDR (as amended). 
 
Prevention and treatment 
 
The following conclusions are relevant to Recommendations 5, 6, 7 and 8; relating to 
prevention and treatment.  
 
10.13. GHBRS can cause profound unconsciousness and its steep dose-response curve 
puts the user at risk of overdose and death. The harm from this is exacerbated by 
imprecise recreational dosing. The co-ingestion of alcohol, and other depressants 
such as benzodiazepines, is a significant additional risk factor for overdose and 
death.  
 
10.14. GHBRS also have a particularly severe, life-threatening withdrawal syndrome. 
Physical dependence on GHBRS develops quickly (over a few weeks to months 
depending on frequency of use), and withdrawal symptoms can develop within a few 
hours of cessation. In addition, effective clinical management is challenging due to 
the difficulties identifying the withdrawal syndrome, followed by resistance to 
treatment (benzodiazepines) and the high intensity of detoxification (treatment 
contacts and duration). This makes reducing the harms from GHB withdrawal 
challenging for clinicians, leaving individuals more exposed to harms from 
withdrawal. In addition, there is consensus within the literature that GHBRS 
withdrawal has high relapse rates after detoxification, meaning once an individual is 
54 
 
addicted it is difficult for them to break the addiction cycle. The literature is also 
consistent in recommending that more research is needed to investigate effective 
clinical management of withdrawal, and effective relapse prevention.  
 
10.15. There is increased evidence that GHBRS toxicity is significantly represented in 
hospitals and clinical care settings in London [EMCDDA, 2015]. When this is 
considered alongside the estimated low prevalence of GHBRS use at a population 
level, it suggests that GHBRS harms are over-represented in hospitals, suggesting 
that harm from GHBRS may be higher than other drugs.  
 
10.16. In addition to harms from overdose and withdrawal, there is also new evidence of 
mental health harms and harm from crimes facilitated by GHBRS, both of which are 
newly identified since the ACMD last reviewed GHBRS and are important to 
consider for treatment and service provision.  
 
10.17. There is evidence that GHBRS use is associated with sleep disturbances, anxiety 
and mood disorders. There is also new and emerging evidence of the occurrence of 
GHB-induced coma negatively impacting on an individual’s ability to regulate 
emotions, and of GHBRS possibly causing negative effects on associative long-term 
memory processing and performance.  
 
10.18. There is strong new evidence of significant harm due to the criminal use of GHBRS, 
including murder, drug-facilitated sexual assault (DFSA) and robbery. The harms 
resulting from these criminal acts are severe and include death in the most extreme 
instances. Survivors of DFSA may experience a complex wide-ranging combination 
of harms requiring support from several different services. Weaponisation of 
GHBRS is of particular concern because GHBRS are eliminated from the body 
rapidly, meaning it is very difficult to definitively pronounce in criminal cases. In 
addition, GHBRS cause amnesia, meaning victims of crime sometimes do not recall 
they have been the victim of crime, or can remember very little about it. Other 
evidence of social harms is sparse, but the evidence available suggests a reduction 
or loss of an individual’s social and community networks, and a negative impact on 
personal relationships. There was a scarcity of information regarding the effects of 
GHBRS on employment, family life, education and housing.  
 
10.19. GHBRS use is higher amongst the lesbian, gay, bisexual and trans-gender (LGBT) 
groups and particularly amongst men who have sex with men (MSM) within a 
sexualised context. These users are vulnerable to additional harms, including 
sexually transmitted infections (STI), HIV and Hepatitis transmission. MSM using 
GHBRS in chemsex are at risk of sexual assault due to the effects of GHBRS 
(reduced consciousness or coma) rendering the individual unable or less able to 
give or rescind consent during sex. If sexual assault does occur, there is potential 
for significant harm from psychological distress. Additionally, there is significant 
evidence of stigma experienced by LGBT GHBRS users, which is a barrier to 
service access. The complex harms – both physical, mental and social – 
experienced by MSM require specialist sexual assault support, and it is reported 
that users believe that current services do not meet these needs. 
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Treatment 
 
10.20. Treatment services, including drug treatment, sexual health services and A&E, are 
currently under-prepared to treat people with harmful/dependent use of GHBRS due 
to the overlap between physical, mental and social harms from GHBRS drug use, 
along with the chemsex context of use and associated sexual health needs. LGBT 
and MSM individuals report experiencing stigma when attending treatment services 
for GHBRS, due to a lack of expertise or understanding of chemsex, which acts as a 
barrier to treatment access.  
 
10.21. Therefore, there is a need for integrated and open access sexual health and 
substance misuse services in order to reduce harm from GHBRS.  
 
10.22. There is a concern stemming from reports by clinicians of emerging and increasing 
use of GHBRS as a recreational club drug, and in other groups who use them 
outside of a sexual context. Therefore it is important to ensure that all services are 
equally accessible and not exclusive.  
 
Recommendation 5: Better integration of drug treatment and sexual health 
services. Commissioning (including at regional/local level as indicated by need) of open 
access, competent, culturally appropriate, substance use and sexual health services to 
address the inter-related harms and psychosocial aspects of health due to GHBRS use, 
including in the context of sexualised drug use. Integrated treatment models currently 
(as at 2020) exist in the UK and these should be examined to understand best practice. 
 
In high demand areas, the closer integration of drug treatment and sexual health 
services, including co-location, should be further explored for effectiveness, 
underpinned by models of joint funding and commissioning.  In areas of lower 
demand/capacity, commissioners and providers should ensure expert referral pathways 
between services. 
 
Further research into effective service access should be conducted, particularly in areas 
of high prevalence, including A&E and primary care. It is noted that this 
recommendation applies to GHBRS but could also apply to chemsex drugs in general.  
 
Lead organisations: The commissioners of Sexual Health Services (SHS) and 
Substance Misuse Services (SMS); BASHH – in the standards for STI management; PHE 
Health Improvement Division, The Local Government Association (LGA); The Association 
of Directors of Public Health.  
 
Measure of impact  
Delivery: PHE to conduct an annual audit/questionnaire of the SHS, SMS and local 
government to capture presence or co-commissioning, alongside treatment numbers.  
 
Impact: Service user feedback annually undertaken by providers and commissioners 
jointly of service users. Feedback should be collected on: 
• accessibility;  
• acceptability;  
• waiting times for appointment at integrated service; and  
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• out of area attendances.  
 
A surrogate marker for improvement in acceptability of the SMS could be a decrease in 
the proportion of people over time who decline to give their sexual orientation when 
specifically asked by services. These data can be found in the PHE NDTMS data tables 
published annually.  
 
Staff education and training 
10.23. Whilst a significant proportion of GHBRS users experience a range of physical, 
mental and social health harms, few access professional support for fear of 
judgement or concern about chemsex expertise. It is important not just to develop 
knowledge of the drug itself, but also the cultural context of use, and the ability and 
cultural competence of staff to create an environment where a service user can be 
open and honest about associated behaviours such as sexual behaviour.  
 
10.24. There is a lack of available training opportunities for staff who come into contact with 
GHBRS users. Developing better service models (recommendation above) will only 
work if staff are appropriately skilled.  
 
Recommendation 6: Education 
Develop a specialist education pathway for frontline staff in the health and social care 
system who come into contact with GHBRS users. These staff include those within the 
SHS, SMS, and emergency departments (overdose and withdrawal). The specialist 
education pathway should provide staff with relevant training on GHBRS-related harms in 
order to better equip them in managing complex cases and provide essential information 
on drug use, cultural competence and understanding. This should help to deliver a higher 
quality and non-judgemental service, working towards reducing harm and alleviating 
some of the stigma associated with the use of GHBRS. A skilled workforce should also 
enable improved engagement at the first point of contact with the SHS/SMS.  
 
To review and update the chemsex e-Learning module of the Sexual Health and HIV 
training to ensure that the content reflects the importance of not just drug knowledge but 
also covers cultural competence and creating a safe environment for open discussion 
about risks and sexual behaviour.  
 
In addition, for the inclusion of GHBRS within postgraduate programmes and speciality 
nurse training, Diploma of genitourinary (GU) Medicine, and speciality training curricula.  
 
Lead organisations: BASHH; SAAS Advisory Board (NHS England and PHE); the 
Society of Apothecaries; NEPTUNE; Health Education England (HEE); the Academy of 
Royal Colleges; the Royal College of Psychiatrists; the Royal College of Physicians 
(including the Faculty of Forensic and Legal Medicine); postgraduate programmes.  
 
Measure of impact: Training requirements clearly stated in national standards (for 
example, BASHH standards for STI management, speciality training curricula and 
Faculty of Forensic and Legal Medicine national standards), service specifications and 
staff competencies monitored by commissioners and providers. Audit of relevant 
courses/standards for inclusion; metrics of current training courses; provider training 
records (staff continuing professional development (CPD) certification and e-learning 
completions).  
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Individual treatment interventions 
10.25. There is a need for improved management of GHBRS-related chronic harms (sexual 
trauma, stigma) and non-acute GHBRS-related presentations to support services, 
such as elective withdrawal. 
 
Recommendation 7: Treatment interventions 
 
Chronic harms (sexual trauma and stigma) 
Services involved in the management of people who use GHBRS should provide 
comprehensive assessments and evidence-based psychological and social support to 
individuals within a key worker/client context. These should be tailored to the individual 
requirements of the service user according to their specific needs, for example, issues 
related to age, ethnicity, cultural context, diversity and social isolation. For those 
individuals with more complex needs all relevant services should have commissioned, 
clear and timely pathways to care. 
 
Non-acute presentations to support services (for example, elective withdrawal) 
The TOXBASE® clinical guidelines for GHBRS intoxication and withdrawal, which are 
used by emergency department staff, should be emphasised to be of value for non-acute 
services, such as elective detoxification presentations. Support services should access 
TOXBASE® guidelines directly or adapt the content to the local service need.  
 
Lead organisations: PHE; the voluntary sector; NHS Sexual Health and Substance 
Misuse treatment providers; commissioners who have responsibility for funding services 
relevant to the sector.  
 
Measure of impact: Number of individuals accessing sexual health and substance 
misuse treatment, for example, PHE to produce reports using GUMCAD V3 and NDTMS 
data and to monitor an individual’s engagement with the service over time and any 
reduction in drug and sexual risky behaviour. Improved access to and retention in relevant 
service provision.  
 
Information and awareness for at risk groups 
 
10.26. GHBRS have a unique risk profile to people who choose to use them (and to those 
who are given them covertly). GHBRS users can reduce their risk by being provided 
with accurate and timely information regarding:  
• the safest way to manage doses;  
• interactions with other substances;  
• mental health harms from GHB-induced coma; and  
• vulnerability to crimes such as DFSA and robbery.  
 
Recommendation 8: Information and support  
To ensure the availability and promotion of information and support to those who are at 
highest risk of harms associated with GHBRS. This should utilise reliable and up-to-date 
sources of information that are already available on physical, mental and social harms, 
including sexual harms and consent in a chemsex setting. The information should, where 
necessary, be individualised and accessible (for example, in appropriate languages).  
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Current sources of available information include: FRANK, Antidote, Crew. 
 
Lead organisations:  The Department of Health and Social Care; PHE; SAAS; NHS 
England, Wales, Scotland and Northern Ireland; BASHH; third-sector treatment providers; 
relevant non-governmental organisations active in the field. 
 
Measure of impact: Audit of advice (quality and access metrics repeated over time); 
research on reach and uptake of the information; organisations undertake feedback 
exercise with users. 
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Annex A: Chemical structures of the compounds being 
considered in this report 
 
The chemical structures of the compounds considered in this report are given below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
gamma-hydroxyvaleric acid 
(GHV)  
gamma-hydroxybutyric acid 
(GHB) 
gamma-butyrolactone (GBL) 
1,4-butanediol (1,4-BD) 
gamma-valerolactone 
(GVL) 
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Annex B: Quality of evidence 
 
Evidence gathered was considered in line with the Advisory Council on the Misuse of 
Drug’s (ACMD’s) standard operating procedure (SOP) for using evidence in ACMD reports 
[ACMD, 2020]. 
 
The international evidence relating to the clinical management of gamma-hydroxybutyric 
acid (GHB) and gamma-butyrolactone (GBL) overdose, withdrawal and relapse is limited as 
randomised control trials are notably absent. The majority of evidence came from case 
reports and case series, with several small observational studies, retrospective cohort 
studies and analysis of patient records. Despite these limitations, these sources are 
consistent in their reported outcomes and recommendations.  
 
The evidence-base relating to GHB harm is substantial in volume. There is evidence of 
harm from official statistics of mortality and drug-related overdose in emergency 
departments, despite challenges in testing for GHB due to its endogenous nature and fast 
elimination from the body. There is also evidence of GHB harm from service treatment 
records, large-scale surveys, qualitative interview analysis, case reports, case series, and 
observational studies.  
 
There is some evidence of harms relating to GBL, however this is limited due, again, to 
challenges in testing. Evidence of the harms of GBL is largely considered as an extension 
to the evidence of harms of GHB, with many sources referring to GHB and GBL 
concurrently as ‘GHB/GBL’ or ‘G’ (the general term for GHB and GBL). The evidence of 
harms for 1,4-butanediol (1,4-BD) specifically are limited. However, due to GBL and 1,4-BD 
being a prodrug for GHB all evidence of harm relating to GHB can also be considered as 
evidence of harm relating to GBL and 1,4-BD.  
 
There is very limited evidence of harm relating to gamma-hydroxyvaleric acid (GHV) or 
gamma-valerolactone (GVL) from peer-reviewed literature (UK and international 
publications) or from government reports.  
 
The ACMD has also considered international approaches to the legislative control of GHB, 
GBL, 1,4-BD, GHV and GVL when drafting this report (see Annex C).   
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Annex C: International legal status of GHBRS  
 
United States of America 
 
The USA drug control system is founded on the Controlled Substances Act (CSA), which 
lists individual substances, and the Federal Analogue Act, which enables control of 
materials that can be shown to be ‘substantially similar’ (in chemistry and effect) to a 
material already listed in Schedule I or II of the CSA. 
 
Gamma-hydroxybutyric acid (GHB) is placed in Schedule I of the CSA (except if in the form 
of Food and Drug Administration- [FDA]-approved products – such as Xyrem – in which 
case the drug is in Schedule III of the CSA). The result of this scheduling is that anyone 
who manufactures, distributes, dispenses, imports/exports GHB or conducts research with 
GHB must apply for ‘Schedule I registration’. 
 
Gamma-butyrolactone (GBL) – as a precursor to GHB – is considered a ‘List I’ chemical 
under the CSA. As a List I chemical, all distributers interested in handling GBL must comply 
with requirements surrounding registration, records/reports, imports/exports and 
administrative inspection [US Department of Justice, 2000].  
 
Although GBL is treated as a drug precursor under US legislation for the manufacture of 
GHB, in accordance with the same legislation it can also be treated as an analogue of GHB 
under certain conditions if taken for human consumption. The definition of a ‘controlled 
substance analogue’ is covered in 21 US Code 802 Section 32 and includes a stipulation 
that although GBL is a listed chemical, that does not preclude a finding that the chemical is 
a controlled substance analogue (i.e. of GHB).  
 
Australia 
 
Australian legislative controls on serious drugs and precursors is split between the federal, 
state and territory governments. The Commonwealth is responsible for controlling the 
import and export of substances at the border, while the state and territory governments 
have their own legislative controls over the possession and use of controlled substances. 
 
At the federal level, GHB and GBL are listed as border-controlled drugs under the Criminal 
Code Regulations 2019 and as prohibited imports under the Customs (Prohibited Imports) 
Regulations 1956. 1,4-Butanediol (1,4-BD) is not currently (as at 2020) under border control 
in Australia. However, the Australian Government will commence work in the latter half of 
2020 to consider the regulatory impacts on legitimate industry if 1,4-BD were to come under 
border control. 
 
At the state and territory level, GHB and GBL are also controlled under each jurisdiction’s 
drug laws; 1,4-BD is also a controlled substance in all states and territories, except 
Tasmania.  
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Annex D: Anecdotal evidence 
 
The lesbian, gay, bisexual and trans-gender (LGBT) Foundation described a case in 2018 
where it supported a service user who had antisocial behaviour charges made against him 
when he had been found naked in the lift of an apartment block after using gamma-
hydroxybutyric acid (GHB). These charges resulted in him losing his flat and having to stay 
with his brother. By the time he got in touch with the LGBT Foundation, he had credit card 
debt and a bailiff had visited his brother’s house. He was considering leaving his job to 
qualify for debt support, as well as feeling suicidal. He was advised that his access to 
housing would be affected by the antisocial behaviour order, and that his mental health 
needs were unlikely to change this. In this scenario, criminalisation of this service user for 
offences caused as a result of GHB-related intoxication led to direct distress and 
homelessness [LGBT Foundation, 2020].  
 
The LGBT Foundation Manchester commented that “Callers to our helpline and people 
using our services tell us that for them, chemsex is ‘a way of removing emotions from sex’, 
or something they usually do when things are particularly bad in their personal life, 
highlighting the problematic use of GHBRS [GHB and related substances] in the chemsex 
context and its like to mental health” [ibid.]. 
 
From a straw poll of 11 GHB/gamma-butyrolactone (GBL) patients, treated as inpatients at 
the Chapman Barker Unit and/or in the community, co-morbid mental health problems were 
a theme for all the GHB/GBL patients (Addiction Services at Greater Manchester Mental 
Health NHS Foundation Trust).  
 
There are anecdotal reports of an increase in GHBRS use in the last two to three years in 
clubs, particularly by straight people in London (though not exclusively). There were a 
number of news reports in 2018 documenting a mainstream move to using GHBRS. A 
Guardian news article focused on straight clubbers who use ‘G’ because it has “no sugar, 
no calories and no hangover” [Guardian, 2018].  
 
 
  
63 
 
Annex E: Options and views considered for classification and 
scheduling  
 
a) Classification of GHB, GBL and 1,4-butanediol under the Misuse of Drugs Act 
1971 
Over the course of this assessment, the Advisory Council on the Misuse of Drugs’ 
(ACMD’s) Technical Committee considered two options with regard to classification. 
  
(i) Change in classification: GHB, GBL and 1,4-butanediol to move to Class B  
The majority of the ACMD’s Technical Committee supported recommending the movement 
of GHB, GBL and 1,4-BD from Class C to Class B of the MDA. These views included:  
• a significant body of new evidence of the harms of these compounds emerging 
since the ACMD’s last review of their classification, particularly in terms of the 
associated levels of drug-related death and their ‘weaponization’ (use to facilitate 
robbery and sexual assault);  
• the harms of these compounds being most commensurate with compounds in 
Class B of the MDA, and; 
• providing law enforcement agencies with additional tools to tackle offences 
associated with these compounds.  
 
(ii) No change in classification: GHB, GBL and 1,4-butanediol to remain in Class C   
 
Some members of the ACMD Technical Committee did not support of recommending a 
movement of GHB, GBL and 1,4-BD from Class C to Class B of the MDA. These views 
included:  
• A lack of evidence to suggest that reclassification alone would be effective in 
reducing the harms associated with these compounds. 
• Concern of the unintended impacts of reclassification on those using these 
compounds – particularly those from the LGBT community and those using these 
compounds in the Chemsex context specifically. These already vulnerable groups 
could be disproportionality impacted by any changes to the criminal justice 
system.  
• Higher offences applicable to the possession of these compounds could deter 
recreational users who fell victim to a drug facilitated sexual assault from reporting 
their assault to the police.  
• Given that these compounds are often used in combination with Class B or A 
drugs during Chemsex, increasing the penalties for the possession of these 
compounds by moving them to Class B would be unlikely to significantly deter 
misuse or abuse.  
Other possible unintended consequences of reclassification might include:  
• a shift to increased use of GHV/GVL.   
• it may force current GHB users to withdraw from the drug in an uncontrolled way with 
consequent impacts on their physical and mental health.  
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b) Scheduling of GBL and 1,4-butanediol under the Misuse of Drugs Regulations 
2001 
Over the course of this assessment, the Advisory Council on the Misuse of Drugs’ 
(ACMD’s) Technical Committee considered a range of possible options for the scheduling 
of gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) under the Misuse of Drugs 
Regulations 2001 (MDR).  
 
These options gave due consideration to the legitimate industrial uses of GBL and 1,4-BD, 
while also scrutinising the feasibility of additional controls in reducing the harms associated 
with the illicit use of these compounds. These options included (but were not limited to):  
 
• the scheduling of GBL and 1,4-BD under Schedule 1 of the MDR, making their 
legitimate industrial uses subject to a Home Office controlled drugs licensing regime; 
• the creation of a new Schedule under the MDR for compounds utilised by the 
chemical industry but with no known medicinal use; 
• the amendment of Regulation 4B of the MDR to apply additional bespoke restrictions 
for GBL and 1,4-BD without creating a new Schedule under the MDR; and 
• making no amendments to the legislative situation with respect to the scheduling of 
GBL and 1,4-BD under the MDR.  
 
On balance, a majority of the ACMD’s Technical Committee were found to be in support of 
scheduling GBL/1,4-BD under Schedule 1 of the MDR, making their legitimate usage 
subject to a Home Office controlled drugs licensing regime. The Committee noted that this 
option would provide increased clarity for the prosecution of offences involving GBL and 
1,4-BD and would disrupt the unrestricted sale from open-web suppliers of GBL and 1,4-BD 
purporting to be ‘cleaning materials’ when clearly destined for the illicit market. The 
Committee considered that it would be beneficial to use an existing framework (the Home 
Office controlled drugs licensing regime) – a regime to which it would be expected that 
legitimate, large-scale chemical suppliers would be able to adapt – to restrict the illegitimate 
uses of GBL and 1,4-BD. 
 
It was confirmed to the ACMD by the Home Office Drugs and Firearms Licensing Unit (DFLU) 
that the large quantities of GBL and 1,4-BD utilised by the chemical industry would not be 
incompatible with a Home Office Schedule 1 licensing regime. It was acknowledged that a 
volume of GBL/1,4-BD might legitimately be lost at some stages or transfer processes by the 
chemical industry – this could be accounted for, were GBL/1,4-BD made Schedule 1 and 
subject to a licensing regime.  
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Annex F: List of abbreviations used in this report 
 
1,4-BD 1,4-Butanediol 
ACMD Advisory Council on the Misuse of Drugs 
BASHH British Association for Sexual Health and HIV 
BEIS Department for Business, Energy and Industrial Strategy 
CBA Chemical Business Association 
CBT Cognitive behavioural therapy 
CNS Central nervous system 
CPB Chlorophenoxybutyric acid 
CSA Controlled Substances Act 
CSEW Crime Survey for England and Wales 
DFSA Drug facilitated sexual assault 
ED Emergency department 
EMCDDA European Monitoring Centre for Drug and Drug Addiction 
EMDR Eye movement desensitisation and reprocessing 
EuroDEN European Drug Emergency Network 
FDA Food and Drug Administration 
fMRI  functional magnetic resonance imaging 
GBL gamma-butyrolactone  
GBMSM gay, bisexual and men who have sex with men 
GHB gamma-hydroxybutyric acid  
GHBRS gamma-hydroxybutyric acid and related substances 
GHV gamma-hydroxyvaleric acid  
GMSS Gay Men's Sex Survey 
GUMCAD Genitourinary Medicine Clinic Activity Dataset  
GVL gamma-valerolactone  
HIV human immunodeficiency virus 
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ISVA Independent Sexual Violence Adviser  
LGBT Lesbian, Gay, Bisexual and Trans-gender  
LGV Lymphogranuloma venereum  
MCPB γ-2-methyl-4-chlorophenoxybutyric acid 
MCT1 monocarboxylate transporter 1  
MDA Misuse of Drugs Act 1971 
MDR Misuse of Drugs Regulations 2001 
MHRA Medicines and Healthcare products Regulatory Agency 
MSM men who have sex with men 
NDIC National Drug Intelligence Centre  
NDTMS National Drug Treatment Monitoring System  
NHS National Health Service 
NHSBSA National Health Service Business Service Authority 
NICE National Institute for Care and Excellence  
NIS National Infection Service 
NMP n-methyl-pyrrolidone  
NPIS National Poisons Information Service 
NPSAD National Programme of Substance Abuse Deaths 
ONS Office for National Statistics 
PHE Public Health England 
PTSD post-traumatic stress disorder  
RASSO Rape and Serious Sexual Offences  
SARCS sexual assault referral centres  
SDMD Scottish Drug Misuse Database  
SHS Sexual Health Services  
SMMASH 
Social Media, Men Who Have Sex With men, Sexual and Holistic Health 
Study 
SMS Substance Misuse Services  
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STI sexually transmitted infection 
VAWG violence against women and girls  
VCSE voluntary, community and social enterprise 
WEDINOS Welsh Emerging Drugs and Identification of Novel Substances 
WHO World Health Organization 
WNDSM Welsh National Database for Substance Misuse  
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Annex G: ACMD membership, at time of publication  
 
ACMD membership, at time of publication 
Professor Judith Aldridge   Professor of Criminology, University of Manchester 
Dr Kostas Agath 
 
 
Consultant Psychiatrist (addictions), Change Grow 
Live Southwark 
Professor Owen Bowden-
Jones  
Chair of ACMD, Consultant psychiatrist, Central 
North West London NHS Foundation Trust 
Dr Anne Campbell  Lecturer in social work, Queens University Belfast 
Mr Mohammed Fessal  Chief Pharmacist, Change Grow Live  
Dr Emily Finch Clinical Director of the Addictions Clinical 
Academic Group and a consultant psychiatrist for 
South London and Maudsley NHS Trust  
Professor Sarah Galvani Professor of Social Research and Substance Use, 
Manchester Metropolitan University 
 
Lawrence Gibbons Head of Drug Threat (Intelligence Directorate, 
Commodities), National Crime Agency   
Professor Graeme 
Henderson  
Professor of Pharmacology, University of Bristol 
Dr Hilary Hamnett Senior Lecturer in Forensic Science, University of 
Lincoln 
 
Dr Carole Hunter Lead pharmacist at the alcohol and drug recovery 
services, NHS Greater Glasgow and Clyde  
Professor Roger Knaggs Associate Professor in Clinical Pharmacy Practice, 
University of Nottingham  
Professor Tim Millar Professor of Substance Use and Addiction 
Research Strategy Lead, University of Manchester  
Mr Rob Phipps Former Head of Health Development Policy 
Branch, Department of Health, Social Services and 
Public Safety, Northern Ireland  
Harry Shapiro Director, DrugWise  
Dr Richard Stevenson Emergency Medicine Consultant, Glasgow Royal 
Infirmary  
Dr Paul Stokes Reader in Mood Disorders and 
Psychopharmacology, King’s College London  
Dr Ann Sullivan Consultant physician in HIV and Sexual health and 
National co-lead for HIV Surveillance, PHE  
Professor Matthew Sutton Chair in Health Economics, University of 
Manchester  
Professor David Taylor Professor of Psychopharmacology, King’s College, 
London and Director of Pharmacy and Pathology, 
South London and Maudsley NHS Foundation 
Trust  
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ACMD membership, at time of publication 
Professor Simon Thomas Consultant physician and clinical pharmacologist, 
Newcastle Hospitals NHS Foundation Trust and 
Professor of Clinical Pharmacology and 
Therapeutics, Newcastle University  
Dr Derek Tracy Consultant Psychiatrist and Clinical Director, 
Oxleas NHS Foundation Trust  
Ms Rosalie Weetman Public Health Lead (Alcohol, Drugs and Tobacco), 
Derbyshire County Council  
Dr David Wood  Consultant physician and clinical toxicologist, Guys 
and St Thomas’ NHS Trust 
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Annex H: Membership of the ACMD’s Drug use in the Lesbian, 
Gay Bisexual and Trans-gender (LGBT) Community Working 
Group 
 
The table below gives the membership of the Drug Use in the Lesbian, Gay, Bisexual and 
Trans-gender (LGBT) Community Working Group. This report has been produced by the 
Working Group, with support from the Advisory Council on the Misuse of Drugs (ACMD) 
Secretariat. 
 
Member ACMD position Professional role  
Dr Ann Sullivan     ACMD member, 
Working Group Chair  
Consultant in HIV Medicine, Chelsea and 
Westminster Hospital Foundation Trust 
and National co-lead for HIV Surveillance, 
Public Health England 
Dr Richard 
Stevenson  
ACMD member Emergency Medicine Consultant, 
Glasgow Royal Infirmary 
Dr Emily Finch  ACMD member Clinical Director, Southwark, Central Acute 
and Addictions Directorate 
Dr Anne Campbell  ACMD member Programme Director, Masters in Substance 
Use and Substance Use Disorders; Co-
Director, Drug and Alcohol Network 
@QUB, Senior Lecturer in Social Work, 
Queen's University Belfast 
Lawrence Gibbons  ACMD member Head of Drug Threat (Intelligence 
Directorate, Commodities), National Crime 
Agency 
Dr Hilary Hamnett  ACMD member Senior Lecturer in Forensic Science, 
University of Lincoln 
Paul Steinberg  Co-opted member Lead Commissioner, Head of Programme 
and Communications, 
London HIV Prevention Programme  
Dr Michael Brady Co-opted member National Advisor for LGBT Health,  
NHS England 
Monty Moncrieff MBE Co-opted member Chief Executive, London Friend 
Dr Dima Abdulrahim  Co-opted member NEPTUNE (Novel Psychoactive Treatment 
UK Network), ATOMIC (Addiction to 
Medication: Improving Care) Lead 
Researcher and Programme Manager 
Dr David Wood  ACMD member Consultant Physician and Clinical 
Toxicologist, Guy’s and St Thomas’ NHS 
Foundation Trust 
Saye Khoo  Co-opted member Professor in Pharmacology, University of 
Liverpool and Hon Consultant Physician in 
Infectious Diseases, Liverpool University 
Hospitals NHS Foundation Trust. 
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Dr Jonathan 
Dewhurst  
Co-opted member Clinical Lead Consultant, Addiction 
Psychiatrist, Greater Manchester Mental 
Health NHS Foundation Trust 
Duncan Craig OBE Co-opted member Chief Executive Officer, Survivors 
Manchester 
Gaynor Driscoll Co-opted member Head of Commissioning (ASC/PH), 
Integrated Commissioning (Royal Borough 
of Kensington and Chelsea and 
Westminster City Council) 
Dr Seán Cassidy  Co-opted member Specialty Registrar in Genitourinary 
Medicine 
56 Dean Street 
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